Doctors	Organisations/ Designated body	GMC

Licensed doctors who are not trainees must:- Have a connection to one organisation (known as a designated body).- Take part in regular appraisal- Collect supporting information for appraisal: 6 types • CPD (annually) • significant events (annually) • review of complaints and complements (as occur) • quality improvement activity • feedback from colleagues • feedback from patients- Reflect on supporting informationAll trainees must:- Have a connection to either a Local Education Training Board or Deanery- Supporting information and discussion of progress and learning needs as generated for curriculum and training programme.	Organisations are required by the GMC to provide:- a RO new role, responsible for the revalidation recommendation)- an up to date appraisal system and ensure every licensed doctor has a regular appraisal- a sufficient number of trained appraisers- clinical governance systems that can provide supporting information- policies and systems for identifying and responding to concerns about doctors- link with other organisations where doctors work, so information about their practice can be sharedRO makes one of three possible revalidation recommendation to the GMC:- Revalidation- Deferral (request for GMC to provide more time for revalidation decision). Does not affect licence to practise.- Non-engagement (can lose licence)	As the regulator the GMC is responsible for:- setting guidelines- Making the final revalidation decision based on RO’s recommendation (to revalidate; how much time to provide for deferral and whether to refer to a Fitness to Practise Panel)- Provide an Employer Liaison Service to help responsible officers with revalidation and the management of concerns about doctors


 	Small-for-gestational age group (n = 10)	Appropriate-for-gestational age group (n = 7)

Age at delivery (years)	27.3 ± 5.2	26.4 ± 6.5

Gestational age at delivery (weeks)	38.4 ± 1.0	39.7 ± 0.7

Birth weight (grams)	2159 ± 506	3156 ± 301*

TGF-β1 levels at 34 weeks (ng/mL)	32.5 ± 3.2	39.2 ± 9.8*

TGF-β1 levels at 38 weeks (ng/mL)	36.04 ± 4.3	36.7 ± 7.0


Output variable	Predictive variables	R2	B(Coef)	p	95%CI	HL*

Cardiovascular risk (PDAY)	Sex	0.271	0.090	< 0.01	0.044-0.183	0,939

Waist circumference	0.043	< 0.01	0.014-0.136


	Skin Prick	sIgE	APT	History

	A	B	A	B	A	B	A	B

D. pteronyssinus 	59	56	56	56	34	39	52	34

Cat dander	54	44	49	46	12	10	23	30

Grass pollen	65	57	75	59	18	15	33	31

Birch pollen	65	49	65	53	11	17	13	20


	ZA group (n = 27)	Control group (n = 27)

Age (years), mean (SD)	60.1 (11.7)	59.4 (13.3)

Sex, female:male	15:12	14:13

BMI (kg/m2), mean (SD)	26 (4)	25 (5)

Operation time (minutes), mean (SD)a	118 (27)	103 (17)

Blood loss (mL), mean (SD)	502 (312)	387 (162)

Diagnosis (OA/AVN)	16/11	17/10


Mouse	Number	Rate	Theoretical rate	Theoretical value	χ2 test

Total	657	—	—	—	—

WT	153	1	1	164.25

Heterozygous	330	2.06	2	328.5

KO	174	0.98	1	164.25	0.50759


	Number of patients with positive test result(n = 30)

Spices	27

Seeds and nuts	24

Seafood	24

Starch	22

Food additives	21

Vegetables	21

Cheese	20

Fruits	20

Sugar products	20

Other additives	14

Eggs	14

Milk and milk products	14

Infusions	13

Salads	10

Mushrooms	9

Yeast	5

Meat	5


	n = 88

Patient age (years)Mean ± SD	36 ± 9.3

Sex (female/male)n (%)	60/28 (68.19/31.81 %)

BMI (kg/m2)Mean ± SD	48.65 ± 7.71


	Non-interacting	Interacting

unconstrained	Z-score = 8.17, AUC = 93.48%	Z-score = 7.09, AUC = 91.06%

constrained	Z-score = 4.32, AUC = 87.01%	Z-score = 6.94, AUC = 90.07%


	Endocan (pg/ml)	Osteoprotegerin (pmol/l)

Baseline	146 ± 110	4,4 ± 2,4

2 months	168 ± 133	4,5 ± 2,7

4 months	168 ± 134	4,6 ± 2,3

6 months	179 ± 224	4,4 ± 2,0

8 months	196 ± 238	4,3 ± 2,1

Paired sample t-test	p-value = 0,036	p-value = 0,668

Friedman test	Chi-Square: 12,696Asymp. Significance: 0,013	Chi-Square: 8,309Asymp. Significance: 0,081


International source	Range of time requirement in minutes	Average time requirement in minutes

ECDC Round Table Report	< 15–60	40

ProMED-mail	< 15–45	35

WHO Event Information Site (EIS)	< 15–30	25

EPIS for Food- and Waterborne Diseases and Zoonoses (EPIS-FWD)	< 15–30	15

WHO Disease Outbreak News (DON)	< 15–30	20

European Early Warning and Response System (EWRS)	< 15–40	30

Eurosurveillance	< 15–30	25

Emerging Infections (EI) Summary	< 15–45	20

Morbidity and Mortality Weekly Report (MMWR)	< 15	10

WHO Weekly Epidemiological Records (WER)	< 15	10

TOTAL	150–330	230


Agent	Specific mechanism	Highest level of studies	Result

Tauroursodeoxycholic acid	Chemical chaperone	Randomized controlled trials	Improved insulin sensitivity in muscle and liver in obese individuals [86]

Phenylbutyrate	Chemical chaperone	Randomized controlled trials	Improved insulin sensitivity and beta-cell function in lipid-infused individuals [87]

Azoramide	ATF6 activators	Rodents	Improves insulin sensitivity and beta-cell function in obese mice [89]

Valproate	Increasing GRPP78	Rodents	Ameliorates atherosclerosis and hepatic steatosis in Apoe−/−mice [90]

L-Carnitine or carnitine-orotate	Fatty acid transfer for beta-oxidation	Randomized controlled trials	Twelve of 17 studies showing improved insulin sensitivity or glycemic control in type 2 diabetic patients or alleviation of hepatic steatosis [98, 99]

Co-enzyme Q10	Electron carrier from complex I and II to complex III	Randomized controlled trials	No net effect on glycemic control in type 2 diabetic patients [100]

α-lipoic acid	Antioxidant	Randomized controlled trials; rodent	Weight-reducing, glucose-lowering, and insulin-sensitizing effect; prevention of hepatic steatosis [101–110]

Vitamin E	Antioxidant	Randomized controlled trials	Inconsistent results on glycemic control [111–115]; reduced hepatic steatosis [122]

N-acetylcysteine	Antioxidant	Rodents	Prevents diet-induced obesity [116–118]

Peptide SS31	Mitochondria-targeted antioxidant peptide	Rodent	Improved glucose tolerance in diet-induced obese mice [38]

Resveratrol	SIRT1 agonist	Randomized controlled trials	Improved insulin sensitivity and glycemic control in diabetic patients; no effect in nondiabetic patients [120];

GSK5182	Estrogen-related receptor gamma inverse agonist	Rodents	Reduces hyperglycemia due to inhibition of hepatic gluconeogenesis [121]

Trehalose, imanitib	Enhance autophagy	Rodents	Improved glucose tolerance and insulin sensitivity in obese mice [84]

Dh404	Nrf2 activator	Rodents	Increased viability of islet by enhancing autophagy [123]


Factor	Parameter Estimate (95% CI)	P

Mean arterial blood pressure

 Smoker	3.49 (−2.67, 9.64)	.257

 Male sex	−38.45 (−91.78 to 14.88)	.151

 Age	0.25 (−.14 to .64)	.202

 Body mass index	0.19 (−.61 to .99)	.625

 Antihypertensive	1.44 (5.19–8.06)	.662

 CD4+ iTreg count,a per 10-fold increase	20.72 (7.03–34.41)	.004

 Sex-associated CD4+ iTreg frequencyb	−18.40 (−41.80 to 4.99)	.119

Diastolic blood pressure

 Smoker	3.09 (−3.54 to 9.72)	.349

Male sex	−62.14 (−119.59 to −4.70)	.035

 Age	−0.04 (−.45 to .38)	.858

 Body mass index	0.44 (−.42 to 1.30)	.301

 Antihypertensive	1.86 (−5.28 to 8.99)	.600

 CD4+ iTreg count, per 10-fold increase	21.50 (6.75–36.25)	.006

 Sex-associated CD4+ iTreg frequencya,b	−28.07 (−53.27 to −2.87)	.030


Cat no.	Category	No. of questions

Questionnaire 1 (QS1)	24

n/a	Have you ever heard of masesea?	1

1	Acquisition & transmission of T. solium infections	3

2	Acquisition of NCC	2

3	TS in general	3

4	NCC in general	3

5	PCC diagnosis	4

6	PCC treatment	2

7	Relationship between PCC/TS/NCC	3

8	Prevention of PCC/TS/NCC	3

Questionnaire 2 (QS2)	15

1	General knowledge	5

2	Transmission	5

3	Prevention	5


Statement	Agree (%)	Disagree (%)	? (%)

1. A man doesn't reach a orgasm during sexual intercourse. Still, the woman can become pregnant.	50	34	16

2. It is unhealthy to use the oral contraceptive pill for a period longer than 10 years.	44	14	42

3. If a woman uses the oral contraceptive pill, she can become infertile.	22	60	18

4. If a woman uses the oral contraceptive pill, her desire for sex becomes less.	7	73	20

5. The oral contraceptive pill is the most reliable contraceptive method.	49	43	8

6. The injectable contraceptive contains hormones, just as the oral contraceptive pill.	63	6	31

7. An intrauterine device can reside in the uterus without problems for 5 years.	42	20	38

8. A condom is not reliable because it ruptures rapidly.	39	53	8


	Without vaccination	With vaccinationa	Difference

Casesb	59,495	25,281	34,214

 Treated at home	47,622	22,389	25,232

 GP visits	11,453	2,786	8,667

 Hospitalised (community acquired)	2,817	353	2,464

 Hospitalised (nosocomial)	421	106	315

 Deaths	0.65	0.16	0.48

Total QALYs lostc	173	64	109

Total direct costsa (x1000)c	€ 7,470	€ 1,185	€ 6,282

Total indirect costs (x1000) c	€ 2,193	€ 888	€ 1,305


Data set	Variance component (%)

	Among groups	Among populations within group	Within populations

All six cattle breeds	7.80	0.70	91.45

Indigenous and local developed breeds	7.80	1.40	90.80


	Practices in first cohort	Practices in second cohort

Practice characteristic	2006-2008	2009-2011	2009-2011

	N	%	N	%	N	%

Practice type

Single handed	17	25%	18	26%	19	27%

Health center	10	14%	11	16%	8	12%

Other	42	61%	40	58%	42	61%

Practice location1

Urban	23	33%	23	33%	25	36%

Semi-urban	34	49%	34	49%	33	48%

Rural	12	18%	12	18%	11	16%

Average number of patients per practice	4629		4808		4830


Storage time	Test organism exposed to (name of the test)	Staphylococcus aureus	Staphylococcus epidermidis	Micrococcus luteus	Corynebacterium jeikeium	Candida albicans

< 1 min	neutralizer in saline peptone water (neutralizer toxicity test)	1.86 ± 0.05	1.81 ± 0.03	1.77 ± 0.01	1.82 ± 0.02	2.05 ± 0.01

	antiseptic solution (material control test)	0*	0*	0*	0*	0*

	saline peptone water (organism viability test)	1.90 ± 0.05	1.84 ± 0.07	1.74 ± 0.03	1.79 ± 0.02	2.02 ± 0.03

3 h	neutralizer in saline peptone water (neutralizer toxicity test)	1.83 ± 0.02	1.81 ± 0.02	1.72 ± 0.03	1.89 ± 0.08	2.05 ± 0.06

	antiseptic solution (material control test)	0*	0*	0*	0*	0*

	saline peptone water (organism viability test)	1.88 ± 0.06	1.81 ± 0.02	1.73 ± 0.05	1.77 ± 0.08	2.03 ± 0.02


Samples	Number	Gender	Age	Mean age

Controls (n = 15)	7	Male	32–77	51.1 ± 15.3

8	Female	46–61	52.6 ± 4.9

Symptomatic HD (n = 16)	8	Male	48–65	60.6 ± 5.6

8	Female	46–67	55.2 ± 7.3


Age group	Number of patients with condylar changes

20–40 (Group A)	16 (64%)

41–60 (Group B)	22 (88%)

61 and above (Group C)	23 (92%)


Type of Intervention	Overall mean blood : sweat ratio

BDE 28	BDE 47	BDE 99	BDE 100	BDE 153

Exercise (n = 3)	137.2	25.5	4.8	16.9	26.9

Infrared sauna (n = 8)	17.9	32.1	3.25	94.6	71.8

Steam sauna (n = 6)	69.5	26.3	5.6	2.4	121.2


Key barriers	Key facilitators

Capabilities: Stress associated with being an asylum seeker	Stress drove activity

Decision process: Living in limbo	Feeling settled and secure

Resources and environment Lack of money for food and equipment Lack of knowledge of facilities in local area The weather Time Lack of childcare

Social

 Exercising With friends/ family Alone in the UK Cultural influences	Exercising With friends/ family

Knowledge and skills

 The phrase ‘physical activity’ and recommended levels	Levels of exercise and physical activity back home

	Understanding consequences Impact on physical health Weight gain Impact on mental health


Disease	miRNA	Expression level	Contributors

Breast cancer	miR-29a	Up-regulation	Wu et al., J Biomed Biotechnol. (2010) [76]

 	miR-21	 	Asaga et al., Clin Chem. (2011) [77]

Lung cancer	miR-21,1254,574-5p	Up-regulation	Wei et al., Chin J Cancer. (2011) [79]

 	 	 	Foss et al., J Thorac Oncol. (2011) [78]

Hepatocellular carcinoma	miR-16,miR-199a	Down-regulation	Qu et al., J Clin Gastroenterol. (2011) [80]

 	miR-21,miR-122,miR-223	Up-regulation	Xu et al., Mol Carcinog. (2010) [81]

Malignant melanoma	miR-221	Up-regulation	Kanemaru et al., J Dermatol Sci. (2011) [82]

Gastric cancer	miR-1,20a,27a,34,423-5p	Up-regulation	Liu et al., Eur J Cancer. (2011) [83]


		Southern zone	Middle zone	Northern zone

Indication	Medicine name	Before	After	Before	After	Before	After

Malaria	ACTs	53.80	7.70	33.30	0	40.00	0

Asthma	Salbutamol	25.00	7.70	26.70	6.20	0	20.00

Diabetes	Gilbendamide	38.50	30.80	20.00	18.80	60.00	60.00

Cardiovascular disease	Atenolol	58.30	23.10	20.00	25.00	40.00	40.00

Depression	Amitriptyline	58.30	38.50	33.30	50.00	60.00	60.00

Infectious disease	Ciprofloxacin	8.30	0	13.30	6.20	20.00	0

Infectious disease	Co-trimoxazole	25.00	7.70	6.00	6.20	0	0

Infectious disease	Amoxiillin	15.40	7.70	13.30	6.20	20.00	0

Central nervous system disease	Diazepam	15.40	7.70	13.30	6.20	20.00	50.00

Ulcer	Omeprazole	30.80	15.40	26.50	18.80	25.00	50.00


Paper	# of patients	Types of mutations

Bartsch et al 1997 [7]	1	Translocation

Matsumoto et al 1997 [6]	1	Deletion

Møller et al 2008 [8]	2	2 translocations

Fujita et al 2010 [9]	1	Deletion

Oegema et al 2010 [10]	2	2 deletions

Yamamoto et al 2011 [11]	3	3 deletions

van Bon et al 2011 [12]	1	Deletion

Valetto et al 2012 [13]	1	Deletion

Courcet et al 2012 [14]	2	1 deletion, 1 frameshift

O’Roak et al 2012 [15]	3	2 frameshifts, 1 splice site

Okamoto et al 2015 [27]	1	Nonsense

Redin et al 2014 [16]	2	1 nonsense, 1 frameshift

Iglesias et al 2014 [17]	1	Nonsense

Ruaud et al 2015 [19]	2	1 nonsense, 1 missense

van Bon et al 2015 [18]	5	2 nonsense, 3 splice site

Bronicki et al 2015 [20]	10	3 nonsense, 2 missense, 4 frameshift, 1 deletion

Ji et al 2015 [21]	14	3 nonsense, 3 missense, 3 frameshift, 5 deletions


Name	Origin	Sex	C14 Date (calibrated)	Endogenous (%)	Unique (%)	MT and Y haplogroup	Mean autosomal coverage

L	Linton	Female	360–50 BCE	72	54	H1e	1.4

HI1	Hinxton	Male	160 BCE–26 CE	16	63	K1a1b1b, R1b1a2a1a2c	1.3

HI2	Hinxton	Male	170 BCE–80 CE	83	65	H1ag1, R1b1a2a1a2c1	11.8

O1	Oakington	Female	420–570 CE	81	50	U5a2a1	3.8

O2	Oakington	Female	385–535 CE	92	68	H1g1	2.7

O3	Oakington	Female	395–540 CE	95	64	T2a1a	8.2

O4	Oakington	Female	400–545 CE	67	77	H1at1	6.3

HS1	Hinxton	Female	666–770 CE	36	91	H2a2b1	4.4

HS2	Hinxton	Female	631–776 CE	42	74	K1a4a1a2b	3.8

HS3	Hinxton	Female	690–881 CE	16	71	H2a2a1	0.9


Evaluation criteria	Medium range contacts	Long range contacts

Top L/5	.34 (.18)	.30 (.05)

Top L/5, δ = 1	.55 (.27)	.48 (.07)

Top L/5, δ = 2	.64 (.29)	.56 (.08)


 	 	Mean fold change	Upper limit C.I	Lower limit C.I

AHPC	Overexpressed in virulent strains compared to the avirulent ATCC 33658 T

Transcription Ratio of AHPC in the virulent strains compared to ATCC 33658 T:	5.80E + 01	1.38E + 02	2.17E + 01

ATP-F	Overexpressed under iron-deprived conditions

 	Transcription Ratio of the iron-poor cultures compared to the iron-rich ones:	2.50E + 01	4.73E + 01	1.32E + 01

Enolase	Overexpressed under iron-deprived conditions

 	Transcription Ratio of the iron-poor cultures compared to the iron-rich ones:	6.10E + 02	2.23E + 03	1.68E + 02

H-NS	Under-expressed under iron-deprived conditions

 	Transcription Ratio of the iron-rich cultures compared to the iron-poor ones:	1.89E + 03	3.29E + 03	1.09E + 03

VapA	Overexpressed under iron-deprived conditions

 	Transcription Ratio of the iron-poor cultures compared to the iron-rich ones:	3.65E + 01	5.14E + 01	2.64E + 01


Years of formal education	Frequency (% out of n=43)	Frequency of Cognitive Dysfunction (%)	Frequency of normal Cognition (%)	Chi-square (x2) test	p-value

More than 12 years	16 (37.2)	8 (50.0)	8 (50.0)	2.563	0.11 (>0.05)

Less than 12 years	27 (62.8)	20 (74.1)	7 (25.9)


Type/site of TB	HIV-TB group

PTB [n(%)]	25 (20)*

EPTB [n(%)]	98 (80)

DTB [n(%)]	39 (32)

Lung + Pleura + mediastinal LN [n(%)]	11 (9)*

Pleura + RP/mesenteric LN [n(%)]	6 (5)

Lung + pleura [n(%)]	4 (3)

Ascites + RP/mesenteric LN + mediastinal LN [n(%)]	4 (3)

Ascites + hepatosplenomegaly + RP/mesenteric LN + mediastinal LN [n(%)]	3 (2)

Lung + pleura + Ascites + RP/mesenteric LN [n(%)]	3 (2)

Ascites + hepatosplenomegaly + mediastinal LN [n(%)]	2 (2)

Lung + pleura + Ascites + hepatosplenomegaly + RP/mesenteric LN [n(%)]	2 (2)

Lung + pleura + Ileocaecal + RP/mesenteric LN [n(%)]	2 (2)

Cervical LN + mediastinal LN + RP/mesenteric LN [n(%)]	2 (2)

Abdomen [n(%)]	23 (19)

Ascites + RP/mesenteric LN [n(%)]	8 (7)

Ascites + hepatosplenomegaly + RP/mesenteric LN [n(%)]	7 (6)

Ascites + hepatosplenomegaly [n(%)]	4 (3)

Ileocaecal + RP/mesenteric LN [n(%)]	4 (3)

Lymph node [n(%)]	16 (13)

Cervical [n(%)]	10 (8)†

Abdominal [n(%)]	4 (3)

RP + mesenteric LN	2 (2)

RP LN	1 (1)

Periportal + mesenteric LN	1 (1)

Mediastinal [n(%)]	2 (2)

Pleural effusion [n(%)]	11 (9)

CNS [n(%)]	6 (5)

Meningitis [n(%)]	3 (2)

Tuberculoma [n(%)]	2 (2)

Meningitis + Tuberculoma [n(%)]	1 (1)

MTB [n(%)]	2 (2)

Pott's spine [n(%)]	1 (1)


Dataset type	Control dataset	Real sample dataset

Dataset Name	D1	D2	D3	D4	D5	D6

Instrument	LCQ	LTQ	LTQ/FT	LCQ	LTQ	LTQ/FT

Reference or notes	[46]	[55]	unpublished	[44]	[56]	unpublished

Sample	12 purified proteins + 23 peptides	49 purified human proteins	8 purified proteins	Human K562 cell line	Human liver	Human Liver

Data source	the BIATECH Institute (Bothell, WA 98011, USA)	Proteomics Standards Research Group (sPRG) [55]	Beijing proteome Research Center (Beijing 102206, China)	Open Proteomics Database (OPD)[57]	Beijing proteome Research Center (Beijing 102206, China)	Beijing proteome Research Center (Beijing 102206, China)


Result/PCR target positivity	Interpretation/meaning	Action

G3PD 567 bp (+)	Valid results for parasite diagnosis	Conclude diagnostic test observation

pUC 316 bp (+)

L. braziliensis 138 bp (+)

G3PD 567 bp (+)	Valid results for parasite diagnosis despite small loss of DNA in extraction	Conclude diagnostic test observation

pUC 316 bp (-)

L. braziliensis 138 bp (+)

G3PD 567 bp (-)	Valid results for parasite diagnosis despite small degradation of sample	Conclude diagnostic test observation

pUC 316 bp (+)

L. braziliensis 138 bp (+)

G3PD 567 bp (-)	Degradation of DNA sample/presence of PCR inhibitors and/or whole DNA loss during extraction	Repeat diagnostic procedure since the blood sample collection

pUC 316 bp (-)

L. braziliensis 138 bp (-)

G3PD 567 bp (-)	Degradation of DNA sample before extraction	Repeat diagnostic procedure since the blood sample collection

pUC 316 bp (+)

L. braziliensis 138 bp (-)

G3PD 567 bp (+)	Significant DNA loss (affecting mainly parasite genome) during extraction process	Repeat the DNA extraction procedure

pUC 316 bp (-)

L. braziliensis 138 bp (-)

G3PD 567 bp (+)	True negative result for Leishmania detection assured by the positivity of quality controls	Conclude diagnostic test observation

pUC 316 bp (+)

L. braziliensis 138 bp (-)


Microtiter plate [28]	Microtiter plate [29]	RISE [30]

Round 1 (h)	Round 1 (h)	Round 1 (h)

Target incubation	18	Target incubation	2	Target incubation	18

Wash-postcoat	2.25	Wash-postcoat	1.5	Wash-postcoat	4

Phage incubation	1	Phage incubation	1	Cell growth tubes	3

Wash-elution	0.5	Wash-elution	2.25	Infection	3

Infection		Infection		Wash	0.5

- amplification	4.5	- amplification	5	Cell/phage/target incubation	16

Phage recovery	0.5	Phage recovery	18	Phage recovery	0.5

Time	~27 h		~30 h		~45 h

2 additional panning rounds		2 additional panning rounds		3 additional panning rounds

TOTAL TIME	~81 h		~90 h		~180 h


Time Series	Germ layer	TP#	Switching#	Gene#	%	Non-Xover	%	Xover	%

Cerebellar development	Ectoderm	12	48,489	5433	21.6	38,722	79.9	9767	20.1

Human iPS to neuron (wt) 1	Ectoderm	4	45,069	6692	26.5	41,302	91.6	3767	8.4

Trachea epithelia differentiation	Endoderm	19	8389	2458	9.8	6112	72.9	2277	27.1

Adipocyte differentiation	Mesoderm	16	66,087	5996	23.8	57,857	87.5	8230	12.5

Epithelial to mesenchymal	Mesoderm	21	132,661	7004	27.8	109,252	82.4	23,409	17.6

BMM TB activation IL13	Mesoderm	11	825	527	2.1	564	68.4	261	31.6

AoSMC response to IL1b	Mesoderm	10	192	159	0.6	129	67.2	63	32.8

Macrophage response to LPS	Mesoderm	23	32,234	4557	18.1	22,239	69.0	9995	31.0

ES to cardiomyocyte	Mesoderm	13	189	163	0.6	100	52.9	89	47.1

Myoblast to myotube	Mesoderm	9	21,912	4249	16.9	18,735	85.5	3177	14.5


Number	Data Source	Age/years	Professional background

1	Focus group	53	Bereavement counselor

2	Focus group	39	Communication consultant

3	Focus group	46	Director & Trainer PR Company

4	Focus group	50	Dietician

5	Focus group	47	Fitness trainer

6	Focus group	36	General practitioner

7	Focus group	45	Social worker

8	Assignment	55	Facilitator in development sector

9	Assignment	55	Physiotherapist

10	Assignment	69	Counselor

11	Assignment	39	Communication consultant

12	Assignment	61	Nurse practitioner/Health coach

13	Assignment	55	Executive coach

14	Assignment	44	Clinical psychologist

15	Assignment	36	General practitioner

16	Assignment	54	General practitioner

17	Assignment	42	Social Worker


Characteristic	Training set	Testing set	Total

Age

 Median	59	58	59

 Range	38∼85	30∼87	30∼87

Clinical stage

 Stage I	0	0	0

 Stage II	8	13	21

 Stage III	163	158	321

 Stage IV	31	31	62

Vital status

 Living	91	88	179

 Dead	112	116	228


 	All cases (n)	Fatality (n)	CFR(95%CI) (%)	RSE (%)

Pre-intervention period

(Eclampsia patients)	1233	258	20.9(18.7, 23.2)	5.5

Intervention period

(Eclampsia patients)	996	23	2.3(1.4, 3.2)	20.9


Certified Reference Materials	DON Immunosensor (ppm)	ELISA (ppm)	Vendor (ppm)

Wheat	0.3	0.2	0.71

Corn	0.92	1.1	1.88

Roasted coffee	0.19	0.24	0.77


 	Confidence ratings at end of module (N≥294)	Confidence ratings 3–6 Months after completion (N≥106)

Mean1	%2	Mean1	%2

Respondent’s Confidence in his or her ability to:

(a) diagnose depression	1.23	99.7	1.19	100

(b) screen for addictions	1.74	92.4	1.67	94.5

(c) screen for other mental health conditions	1.83	91.8	1.73	96.3

(d) treat depression	1.43	99.0	1.28	100

(e) treat other mental health disorders	1.99	85.2	1.93	87.2

(f) prescribe medications for mental health conditions	1.67	95.0	1.61	95.5

(g) assess patients’ problems and strengths	1.79	91.0	1.66	92.7

(h) develop systematized care plans for patients where a mental health care plan is not appropriate	2.07	77.5	1.86	84.0

(i) create a mental health care plan fitting Medical Service Plan [provincial program] guidelines	1.87	83.4	1.69	89.8

(j) engage mental health patients in a range of interventions (e.g., cognitive behavioural and interpersonal skills training)	1.97	81.4	1.90	82.6

(k) offer and coach the Antidepressant Skills Workbook	1.95	80.2	1.83	85.0

(l) offer and support the Bounce Back program	1.54	92.1	1.56	91.7

(m) In general, how confident are you in the quality of mental health care you provide to your patients?	1.71	96.3	1.46	99.1

Respondent’s confidence in her or his knowledge/awareness of:

(a) non-pharmacological interventions (cognitive behavioral skills such as activation, relaxation, negative thinking)	1.90	86.8	1.76	91.7

(b) regional mental health resources for mental health patients	2.05	82.8	1.87	88.1


Reaction	Genes	Primer names	Forward primer sequence	Reverse primer sequence	Size (bp)

	hsp60 (groEL_1)	hsp3/hsp4	GACCGCCAGTTAAGATAGCG	TCTCTAGCTACTTCGCAACAAATCC	297

1	CTL0626	CTL06265'F/CTL06265'R	GCACACCATCACTATCAC	GCGCTTGCTTGAGATTTC	226

2	CTL0627	CTL06275'F/CTL06275'R	GTTGGCGAGTCCGATGATG	GACTTCTAATACAGCACCATGTTTG	195

3	CTL0628	CTL06285'F/CTL06285'R	GAAACGGTCTCCTACTAGC	GGTGGGAAGAAATAGTTAAGG	357


Impact factors	P-value	Impact factors	P-value

Epidemiologic information		Chemotherapy detail

Age at diagnosis	0.335	PEB/PVB	0.043

Ethnic group	0.856	Bleomycin/pingyangmycin	0.755

Individual history		Weekly/monthly	0.031

Prior lung disease	1.000	Route of administration	0.041

Allergic history	0.603	Cumulative dose	0.000

Disease state		Average course interval	0.256

Stage of disease	0.081	Combined treatment

Histological subtype	0.741	G-CSF	0.331

Side effects of treatment		Antibiotics	0.904

Renal dysfunction	0.001	Blood transfusion	-

Drug allergy	0.332	Erythrocyte	0.116

Granulopenia	0.176	Thrombocyte	0.035

Anemia	0.041	Chalybeate	0.067

Thrombocytopenia	0.000	Post-chemotherapy surgery	0.072


>Stage of development	>WT versus AS	>WT versus OE

Immature green	234	333

Mature green	68	112

Red ripe	105	332

Total	407	777


No.	shRNA Targets of RB1

siRNA-RB1-2	GGGUUGUGUCGAAAUUGGATT

siRNA-RB1-4	GGAGUAUGAUUCUAUUAUATT

Negative control siRNA (NC siRNA)	UUCUCCGAACGUGUCACGUTT


Module I: Basic concepts in global health

01.	Defining and measuring global health

02.	Global health definitions, case studies

03.	Historical origin and evolution

04.	Health systems and global health

Module II: Understanding the key global health challenges

01.	Current global health status

02.	Global burden of disease

03.	Global health priorities for twenty-first century

04.	Global health at the human–animal–ecosystem interface

Module III: Cross-cutting themes in global health and emerging trends

01.	Environment, climate, and migration

02.	Food, water, and sanitation

03.	Health disparities

04.	Women’s health

05.	Emerging, remerging infectious diseases

06.	NCD and injuries

07.	Maternal and child health

08.	Childhood immunization

09.	Adolescent health

10.	Neglected tropical diseases

11.	Antimicrobial resistance

Module IV: Global health diplomacy

01.	Overview of global health diplomacy

02.	Global health actors and activities

03.	Global health financing

04.	Global health policy and governance

05.	Drivers of policy for global health diplomacy

06.	Globalization, trade, work, and health

07.	Foreign policy and health

Module V: Global health security

01.	Global health security

02.	Pandemics and health security responses

03.	Health in complex humanitarian emergencies

04.	Humanitarian response and humanitarian dilemmas

05.	Global health equity

06.	Values in global health

07.	Toward a social justice approach to global health

Module VI: Research, development, innovation, and technology for global health

01.	The environment, sustainable development, and health

02.	Universal health coverage in the context of aging

03.	Sustaining good health with equity at low cost

04.	Science and technology for global health

05.	Scaling up effective models in global health delivery


Questions	Partners	Regenstrief	Intermountain Health Care	Veterans' Health Administration

CIS modules offered (products that have capability to provide decision support)?	Yes, CPOE, results review, laboratory, outpatient clinical documentation, eMAR, Drug-Drug/Allergy/Lab Interaction checking. BCMA	Yes, CPOE, consults from specialists. Documentation: patient visit notes, ADT summaries, problem lists. Links to test results, notes	Yes, Antibiotic, TPN; Results review; RN, RT, Pharmacist charting; Infection & Disease monitoring, ADR triggers, VTE high risk alerts	Yes, Order menus, sets, quick orders. documentation. Templates. Drug-Drug/Allergy/Lab Interaction checking. BCMA

EHR delivery model?	Onsite	Onsite	Onsite (Server and web based)	Onsite (move to regional server)

CDS content implemented/configured/maintained by customer or vendor?	maintained by informaticians. Most content separate from code viewed thru repository	Clinician/Informaticians update terminology and decision support rules as needed	Users responsible for content. Programmers logic. Updated weekly, larger updates quarterly	CDS maintained, implemented locally. National releases with local configuration.

Collect structured data and which controlled vocabularies?	LOINC, RxNorm, SNOMED, ICD-9, CPT, FDB	ICD-9 & CPT codes avail. Most entered via Regenstrief Dict. mapped to standard vocabs.	Mostly coded data, some dictated notes as free text. LOINC, SNOMED, ICD-9	Not from clinician notes, but reminder templates do. ICD-9 for problem list

Support ad-hoc queries? Live replicating database?	Yes. Yes, weekly to monthly depending on data element	Queries done by data analysts on real database, in response to requests from end users.	Yes, but most reports run on EDW from programmers. Have some canned reports monthly	Yes, use replicated DB, varied update frequency; ProClarity data cubes

HL7 InfoButton?	Yes	No	Yes	No, but something similar

Arden Syntax for MLM?	No	No. Gopher Care Rules corresponds to Arden Syntax.	No (some graduate projects)	No

Clinical knowledge editor for user to create CDS?	Yes	Editor used by infomaticians to create CDS	Ability for knowledgeable users to create CDS	Not by end user. Some local configuration by support staff

Content mgmt system separate from EHR?	Yes	No	Online K repository, most review/updates programmers	No. Pilots are ongoing.

Reporting capability to track effect/usage of CDS content?	Yes	User responses prospectively, not retrospective	Yes, from reports in the EDW	Yes, focused on performance measures not CDS usage

Drug database supplier?	FDB	In-house drug terms	FDB	Internal Drug/Allergy files

3rd party CDS content vendors?	Thompson Micromedex, UpToDate	No	MicroMedex through Info-buttons	MicroMedex, UpToDate, etc. at point of care

Provide clinical content (starter sets). What content is included, how and how often and is it updated?	CDS content provided and maintained by the Informatics groups. Updates distributed on an as needed basis.	Alerts, drug-drug. Formulary, price. Order sets. Default drug strengths, frequencies, or instructions. updates mult/yr.	All alert logic is provided, developed, and maintained by institution. weekly and quarterly updates	Local development of reminders, order menus, document templates.

On-line collaborative knowledge development environment web 2.0?	Yes	No	No	Yes, starting SharePoint sites for national groups

Internet repository for clients to share locally generated CDS?	No	No	No	Some networks have web sites to share CDS


	H3K27me3	P value

Low	High	Total

pS9-GSK3β

 Low	13	10	23

 High	23	64	87

 Total	36	74	110

				0.006


Humans and Great Apes	All other mammals e.g. mouse	Peptide abbreviation	Gene name

Relaxin-1	Relaxin#	RLX1	RLN1

Relaxin-2#		RLX2	RLN2

Relaxin-3	Relaxin-3	RLX3	RLN3


Identifier	Best Arabidopsis match	Possible function	Position (kb)	Gene ID

C2H2 TF	AT3G18290	RING finger and CHY zinc finger encoding BRUTUS (BTS), E3 ligase protein with metal ion binding and DNA binding domains, which negatively regulates the response to iron deficiency	1,000	MDP0000283750

C2H2 TF	AT1G68360	C2H2 and C2HC zinc finger family	1,020	MPD0000183099

MdMYB7	AT1G68320	MYB involved in regulation of phosphate starvation responses and gibberellic acid biosynthesis.	1,070	MDP0000659260

bHLH	AT1G25330	bHLH75, BR enhanced	1,080	MDP0000725991

COL	AT1G68520	Contans-like light regulation of secondary metabolites	1,220	MDP0000185616

bZIP	AT1G68640	HBP-1b(c1), BZIP - PAN is essential for AG activation in early flowering	1,380	MDP0000250967

MdG2L6	AT1G25550	Golden-like ARR18 MYB-related	1,440	MDP0000202657

MdAP2D36 TF	AT1G68840	Regulator of vac ATPase Rav2 is part of a complex that has been named 'regulator of the (H+)-ATPase of the vacuolar and endosomal membranes' (RAVE)	1,480	MDP0000939633

LAR1		MdLAR1	1,540	MDP0000376284

bHLH	AT1G68810	Known bHLH, no other function	1,550	MDP0000319726

bHLH	AT1G68920	bHLH49 Known bHLH, no other function	1,890	MDP0000154272

MdbHLH21	AT1G69010	BES1-INTERACTING MYC-LIKE PROTEIN 2	1,970	MDP0000149222


Week	Weekly theme

1	Introduction and briefing on the aims of the rehabilitation program• Introduction to group• Introduction of the concept of self-efficacy• Information on post-stroke balance self-efficacy and rehabilitation

2	Understanding the relationships between thoughts, emotions, and behavior• Introduction to the CBT model• Understanding fear, fear of falling, fall risks, and actual falls• Understanding the automatic thoughts and emotional and behavioral reflection associated with fear of falling

3	Exploring thoughts and maladaptive responses• Identifying maladaptive thoughts leading to physical inactivity• Adapting realistic views of fall risk and the consequences of falls• Recognizing risky behavior• Overcoming barriers to physical activity

4	Exploring adaptive thoughts and behavioral responses• Fall prevention strategies and safety issues• Recognizing and minimizing fall risk

5	Implementing and reviewing behavioral changes related to ADL• Setting personal goals for ADL• Planning to achieve personal goals in small stages• Recognizing potential hazards and planning for safety

6	Implementing and reviewing behavioral changes related to social activities• Setting personal goals for social activities• Planning to achieve personal goals in small stages• Recognizing potential hazards and planning for safety

7	Reviewing and advancing individual therapeutic goals• Reviewing personal goals for ADL and social activities• Establishing a regular exercise plan

8	Consolidating the experiences of the rehabilitation program• Sharing attitudes and experiences of fear of falling before and after the group• Sharing experiences of applying cognitive-restructuring skills• Establishing the long-term personal goals of regular exercise, ADL independence, and social engagement


	Athletes	Controls	P‐values

Baseline characteristics

n	19	8

Age (year)	26 ± 5	31 ± 4	0.07

Height (m)	1.77 ± 0.08	1.80 ± 0.10	0.47

Body mass (kg)	72.6 ± 9.5	84.1 ± 12.2	0.02

Body mass index (kg/m2)	23 ± 2	26 ± 3	0.01

Maximal oxygen uptake (mL/kg·min−1)	55.9 ± 4.9	39.2 ± 5.0	<0.001

Resting values

n	19	8

Heart rate (bpm)	54 ± 8	58 ± 5	0.20

Mean arterial pressure (mmHg)	73 ± 10	74 ± 10	0.92

Middle cerebral artery mean blood velocity (cm/sec)	63.9 ± 11.7	65.5 ± 14.8	0.75

Cerebrovascular conductance index (cm sec−1 mmHg−1)	0.88 ± 0.14	0.91 ± 0.23	0.72


	Healthy (n = 18)	Post-OP (n = 28)	Sepsis (n = 15)

IL-6 (pg/ml)	0.0; 0.0–0.8	216.7; 48.8–360.5	577.7; 521.9–583.2

P-value	Healthy versus Post-OP: P < .001***

Healthy versus Sepsis: P < .001***

Post-OP versus Sepsis: P <.001***

TRX1 (ng/ml)	11.0; 10.0–12.1	11.3; 9.6–15.6	34.0; 19.7–57.7

P-value	Healthy versus Post-OP: P = .458

Healthy versus Sepsis: P < .001***

Post-OP versus Sepsis: P <.001***

MIF (pg/ml)	161.6; 148.5–214.0	156.4; 115.1–398.7	1821.1; 412.2–3708

P-value	Healthy versus Post-OP: P = .954

Healthy versus Sepsis: P = .005**

Post-OP versus Sepsis: P < .001***


No.	Age	Sex	AQP1/4 tissue	Brief history	Probable cause/

 	(years)	 	immunoreactivity*	 	underlying cause of

 	 	 	 	 	CPM

1	56	M	0	Alcoholism; nausea and vomiting 1 week; hyponatremia, abnormal liver function tests; presented to Emergency Room in cardiorespiratory arrest.	Rapid correction of hyponatremia

2	53	M	0	Depression and chronic obstructive pulmonary disease. Not seen for 4 days; found dehydrated and malnourished; drug and alcohol screen negative.	Dehydration, malnutrition and hypernatremia

3	33	M	0	Cryptogenic cirrhosis with antitrypsin heterozygosity; orthotopic liver transplant and hyponatremia followed by progressive obtundation and seizures.	Orthotopic liver transplant

4	45	M	0	Small-cell lung carcinoma, metastatic to liver; abnormal liver function tests; possible malnutrition; hyperkalemia; several syncopal episodes in preceding hours; presented with respiratory failure.	SIAD secondary to small-cell lung carcinoma

5	24	F	↑	Hepatic failure and autoimmune thrombocytopenic purpura, 6 months; altered consciousness level and nonconvulsive status epilepticus 5 weeks before death; hypocalcemia, hyperammonemia and elevated liver enzymes.	Hepatic failure and hypocalcemia

6	68	F	↑	Hypertension, obesity, diabetes mellitus, hyperuricemia and remote endometrial carcinoma (treated by resection, chemotherapy, and radiotherapy); presented with gangrene of the right fifth toe; generalized seizure followed by unresponsiveness.	Diabetes mellitus type II


Health risk behavior	Men	Women

	N	(%)	N	(%)

Current smoking	10784	(57.3)	3099	(15.6)

Excess alcohol consumption	5177	(27.4)	1155	(5.8)

Physical inactivity	13989	(71.2)	14926	(72.0)

Poor dietary habits	7974	(40.6)	5671	(27.4)

Stress	9639	(51.9)	12151	(61.3)

Non-attendance of health check-ups	5243	(27.5)	8532	(42.3)


			Microaerobic culture

			+	-	Total

4.1 Campylobacter coli detection in faecal samples		+	125	1	126

	Real-time PCR	-	3	17	20

		Total	128	18	146

4.2 Campylobacter coli detection in feed samples		+	21	1	22

	Real-time PCR	-	2	26	28

		Total	23	27	50

4.3 Campylobacter coli detection in environmental samples		+	34	2	36

	Real-time PCR	-	3	47	50

		Total	37	49	86


Sequences	Descent	Ascent	Stop (Life Bases)	P

n	%	n	%	n	%

Feeling pain (FP)	10	31.2	14	43.8	8	25	0.4633

Putting meaning to those feelings (PM)	5	17.8	16	57.2	7	25	0.0269 *

Adjusting running style (AR)	6	40	7	46.6	2	13.4	0.3593

Attempting to overcome the problem (OP)	0	0	0	0	7	100	0.0009 *

Influence of other runners (IR)	0	0	5	23.8	16	76.2	0.0005 *

Assessing the overall situation (AS)	3	10.3	5	17.3	21	74.4	0.0005 *

Total	24	18.2	47	35.6	61	46.2	0.0003 *


	Number	Incidence (%)	Anomalies (%)

Benign anomalies

CA from RCS	8	1.07	24.24

Absence of LMA	7	0.93	21.21

Posterior RCA	1	0.13	3.03

Potentially clinically significant anomalies

Superior RCA	7	0.93	21.21

CFX from RCS	4	0.53	12.12

CFX from RCA	2	0.26	6.06

Coronary fistula	1	0.13	3.03

Coronary aneurysm	1	0.13	3.03


Metric	Value

Families making <Q 2000a per month	66 %

Families making Q 2000–4000a per month	34 %

Average persons per household	6.4

Average children per household	3.3


	Study 1	Study 2

Age, y	24 ± 4	26 ± 3

Body mass, kg	72.9 ± 3.9	65.8 ± 9.0

Height, m	1.70 ± 0.09	1.70 ± 0.10

BMI, kg/m2	25.0 ± 1.1	22.8 ± 0.9

Body fat, kg	24.2 ± 11.4	19.3 ± 3.7

Body fat, %	32.4 ± 2.0	29.8 ± 6.5

Lean mass, kg	45.3 ± 8.1	43.6 ± 8.7

Peak bike power, watts	n/a	145 ± 43

Peak VO2, mL/kg/min	n/a	26.4 ± 5.9

Peak heart rate, beats/min	n/a	179 ± 15

Total cholesterol, mmol/L	3.98 ± 0.99	4.03 ± 0.90

HDL cholesterol, mmol/L	1.21 ± 0.37	1.11 ± 0.33

Triglycerides, mmol/L	0.74 ± 0.39	0.89 ± 0.31

C-reactive protein, nmol/L	18.4 ± 19.9	11.0 ± 5.2

Glucose, mmol/L	4.7 ± 0.2	4.8 ± 0.5

Insulin, pmol/L	41 ± 28	41 ± 27

Systolic blood pressure, mmHg	109 ± 9	112 ± 10

Diastolic blood pressure, mmHg	68 ± 8	62 ± 7


Compound	LOD (μg/L)	LOQ (μg/L)	RSD (%)	Recovery (%)	Method	References

Caffeine	3610	10,940	1.7	95 ± 7	HPLC–DAD–MS	[4]

Theobromine	30	100	6.5	97 ± 3

Trigonelline	3770	11,420	1.0	102 ± 2

Caffeine	80	–	0.20–6.2	99 ± 3	HPLC–UV	[9]

Theobromine	140	2.8–9.1	103 ± 6

Trigonelline	260	1.1–5.0	99 ± 5

Caffeine	11.9	39.6	2.1–4.7	97 ± 4	LC–MS	[12]

Theobromine	–	–	–	–

Trigonelline	36.4	121.5	3.2–3.5	140 ± 16

Caffeine	2	40	3	99 ± 2	Fluorescence	This study

Theobromine	6	20	3	–

Trigonelline	7	20	4	99 ± 2


Inclusion Criteria	Exclusion Criteria

◆ Student at Haskell Indian Nations University◆ Age at least 18 years or older◆ Have a valid college/university email address, telephone number, and home address◆ Willing to participate in all study components◆ Willing to be followed-up over several years (1-4 years, depending on freshman cohort year)	◆ Planning to leave or graduate from the University before the end of the current academic year◆ Unable to participate in all components of the study


	Food-specific decentering	Awareness of food thoughts	Meditation experience

Food cravings	−0.62a	0.27	−0.47 a

Food-specific decentering		−0.29	0.25

Awareness of food thoughts			−0.20


MolNo.	R1	R2	Predicted activity	Lipinski’s scoreandScreen

R-1	4-nitrophenyl	4-methoxyphenyl	0.8564	ADRXWS (6)

R-2	4-nitrophenyl	4-nitrophenyl	-0.3876	ADRXWS (6)

R-3	Benzyl	4-hydroxyphenyl	0.9765	ADRXWS (6)

R-4	3-aminophenyl	4-nitrophenyl	0.8450	ADRXWS (6)


Percent of invaded area	Himalayan blackberry	English ivy

In clusters	98.5	99.3

In outliers	1.5	0.7


KDQOL-36TM Subscales	Mean	SD	Minimal (Floor%)	Maximal (Ceiling%)

Symptoms/problems list	74.22	15.24	37.50 (1)	100 (2.9)

Effects of kidney disease	54.78	20.10	00.00 (1)	96.88 (1)

Burden of kidney disease	33.07	23.31	00.00 (13.6)	100 (1)

Physical Composite Sore	36.60	7.83	17.05 (1)	54.92 (1)

Mental Composite Score	46.82	9.81	22.17 (1)	65.09 (1)


	Local density	Coeff. variation nearest distances	Area

Local density	1.00	---	---

Coeff. Variation nearest distances	0.22*	1.00	---

Area	-0.10	0.11	1.00


Variable	Factor	P value	HR	95.0% CI

Age	Continuous	0.367	1.02	0.98–1.05

Sex	Male	0.001	0.36	0.20–0.66

ECOG-PS	>1	0.034	2.13	1.06–3.39

Comorbidities (CVD or DM)	Positive	0.084	0.53	0.25–1.07

Metastatic disease	Positive	<0.001	9.34	5.12–17.1

Frailty discriminant score	>2.30	0.005	3.03	1.41–5.51


miRNA	Target	Effector cell	Affected chemokine	Role in atherosclerosis	References

miR-181b	Importin-α3	ECs	CXCL1	Protective	[58]

miR-103	KLF4	ECs	CXCL1CCL2	Damaging	Unpublished

miR-126-3p	RGS16	ECs	CXCL12	Protective	[64]

miR-10a	TAK1, β‐TRC	ECs	CCL2	Protective	[87]

miR-92a	KLF2, KLF4, SOCS5	ECs	CCL2CXCL1?	Damaging	[88]

miR-21	PPARα	ECs	CCL2	Damaging	[79]

let-7g	THBS1, TGFBR1, SMAD2	ECs	CCL2	Protective	[97]

miR-155	BCL6	Macrophages	CCL2	Damaging	[43]

miR-342-5p	AKT1	Macrophages	CCL2 (via miR-155)	Damaging	[102]

miR-467b	LPL	Macrophages	CCL2	Protective	[105]

miR-24	CHI3L1	Macrophages	CCL2	Protective	[108]


	Groups

	NH	CI

	Long, complex sentences	Highly meaningful sentences	Nonsense sentences	Long, complex sentences	Highly meaningful sentences	Nonsense sentences

Verbal Working Memory

LSpan (total letters correctly recalled)	.10	.05	.07	.64**	.57**	.68**

Rspan (total letters correctly recalled)	‐.01	.06	.13	‐.03	.01	‐.02

Modality‐General Neurocognitive Scores

Attention Sustained (scaled score)	.14	.07	‐.08	.14	.19	.29

Forward Memory (scaled score)	‐.10	‐.35	.17	.23	.23	.14

Reverse Memory (scaled score)	.06	‐.11	.08	.20	.20	.04

Verbal Stroop–Congruent (response time)	‐.04	.20	.07	‐.28	‐.29	‐.36

Verbal Stroop–Incongruent (response time)	‐.14	‐.05	‐.03	‐.41*	‐.43*	‐.43*

* p‐value < 0.05

** p‐value < 0.01CI = cochlear impant; LSpan = Listening Span; NH = normal hearing; RSpan = Reading Span


Variables	Unstandardised coefficients (B)	S.E	Standardised coefficients (Beta)	P value

Age	− 0.020	0.017	− 0.066	0.241

Marital status	0.052	0.041	0.077	0.205

Income level	0.064	0.023	0.163	0.006

The current condition	− 0.023	0.019	− 0.074	0.222

Pain severity score	− 0.011	0.002	− 0.353	< 0.001

Pain interference score	− 0.007	0.001	− 0.350	< 0.001

Post-treatment pain	− 0.010	0.051	− 0.012	0.842


Kinases	Phosphatases	Growth factors	Cytokines	Transcription factors

Fgfr1	Acpp	Clec11a	Il10	Gata6

Pdk4	Dusp23	Gas6	Pf4	Lass4

Srms	Nt5e	Gdf6	Thpo	Lhx4

Srk3	Pon1	Igf1	Wnt5a	Nfatc2

	Ppap2b	Igf2		Per2

		Inhbe		Tal1

		Mst1		Tcf7l2

				Sox9


Gene ID	I_CN	I_0	Annotation

Kinase

 Unigene43155_xckb	D_U	F_F	Proline-rich receptor-like protein kinase PERK2

 Unigene66089_xckb	U_D	F_F	G-type lectin S-receptor-like serine/threonine-protein kinase SD1-13

 Unigene13595_xckb	U_D	F_F	Protein kinase domain containing protein

 CL3347.Contig1_xckb	U_D	F_F	Cysteine-rich receptor-like protein kinase 8

 Unigene60834_xckb	U_D	F_F	Probable LRR receptor-like serine/threonine-protein kinase At4g29180

 Unigene68690_xckb	U_D	F_F	Proline-rich receptor-like protein kinase PERK10

 Unigene35121_xckb	U_D	F_F	Proline-rich receptor-like protein kinase PERK2

TF

 Unigene65053_xckb	U_D	F_F	MADS-box transcription factor 15

 Unigene34602_xckb	U_F	F_F	Ethylene-responsive transcription factor ABI4

 Unigene69673_xckb	U_F	F_F	Ethylene-responsive transcription factor ERF109

Resistance

 Unigene68271_xckb	U_D	F_F	Leucine-rich repeat extensin-like protein 3

 CL2708.Contig2_xckb	U_D	F_F	Pollen-specific leucine-rich repeat extensin-like protein 1

 Unigene72805_xckb	U_D	F_F	Resistance protein RGA2

 CL6805.Contig1_xckb	F_U	F_F	Hydroxyproline-rich glycoprotein gp1

 Unigene48841_xckb	F_U	F_F	Hydroxyproline-rich glycoprotein gp1

 Unigene46836_xckb	U_D	F_F	Hydroxyproline-rich glycoprotein gp1

 Unigene72060_xckb	U_D	F_F	Hydroxyproline-rich glycoprotein gp1


Diagnosis	Cases

Head injury	7

Skin lesions	5

Poisoning	4

Polytrauma	3

Others	2


Kind of complications	n = 20 (23.2 %)	Need for reoperation n = 19 (22.0 %)	Way the complication was handled

- Femoral shaft fracture	4 (4.6 %)	4 (4.6 %)	cerclage, cemented stem

- Calcar fracture	1 (1.2 %)	1 (1.2 %)	change of approach

- Dislocation	2 (2.3 %)	2 (2.3 %)	closed reduction

- Sintering	1 (1.2 %)	1 (1.2 %)	larger neck size

- Periprosthetic fracture	6 (6.9 %)	6 (6.9 %)	plate osteosynthesis, cerclage, cemented stem, augmentation, total exchange

- Cup displacement	1 (1.2 %)	1 (1.2 %)	cemented cup

- Infection	2 (2.3 %)	2 (2.3 %)	exchange of head & inlay

- Hematoma	3 (3.5 %)	2 (2.3 %)	lavage, punction

- Thrombosis (%)	0 (0.0 %)	0 (0.0 %)	-

- Pulmonary embolism (%)	0 (0.0 %)	0 (0.0 %)	-


Demographic Data	Diabetes Medication	Frequency

Male (%)	44 (61)	OHA	39

Female (%)	28 (39)	Insulin	7

Mean age	56	OHA + Insulin	18

Median age	59	Nil	8

Mean BMI	39	HbA1c	(mmol/mol)

Median BMI	39	Mean HbA1c	67

		Median Hb A1c	57


Test	Occlusive patch (means)	Scotogenic lens (means)	Significance (K–S test), p value

Symptom control	9.73	9.27	0.985

Comfort	4.36	7.45	0.047

Aesthetics	2.00	9.45	<0.001

Overall assessment	4.18	8.54	<0.001


Assays	Treatment Group	MeanCFU Counts	Treatment Effect Group

CFU-GM	N	79.3	A

	APS	52.3		B

	TPO	50.0		B

	C	34.5			C

BFU-E	N	55.3	A

	TPO	31.2		B

	APS	22.3			C

	C	8.3				D

CFU-GEMM	N	27.7	A

	APS	19.7		B

	TPO	18.0		B

	C	8.3			C

CFU-MK	N	51.8	A

	APS	32.5		B

	TPO	37.5		B

	C	15.3			C

CFU-F	N	29.8	A

	APS	27.6	A

	TPO	19.3		B

	C	8.8			C


Case	Age	Disease recurrence	Presence of metastasis*	Follow-up (months)	Life status

1	41	No	No	64	Alive

2	37	No	Yes	22	Alive

3	55	NI	NI	NI	NI

4	59	No	Yes	16	Dead

5	46	No	No	107	Alive

6	27	No	No	28	Alive

7	33	Yes	No	36	Alive

8	67	No	No	34	Alive

9	40	No	No	35	Alive

10	54	No	Yes	48	Dead

11	57	Yes	No	30	Alive

12	61	No	No	9	Alive

13	67	No	No	32	Alive

14	38	No	No	17	Alive

15	71	No	No	5	Alive

16	40	No	No	87	Alive

17	40	No	No	10	Alive

18	58	No	Yes	47	Dead

19	47	No	No	22	Alive

20	41	No	No	14	Alive

21	39	No	Yes	9	Dead

22	40	No	Yes	48	Alive

23	45	No	No	35	Alive

24	53	No	Yes	13	Alive

25	29	No	Yes	14	Dead

26	36	No	Yes	19	Dead

27	24	No	Yes	6	Alive

28	48	No	Yes	NI	Dead

29	56	No	No	22	Alive

30	77	No	Yes	17	Alive


	Prior to replacement (RR*, 95% CI)	Subsequent to replacement(RR, 95% CI)

All Outdoor Injuries	1.65 (1.50-1.82)	2.07 (1.91-2.24)

Non-equipment injuries	1.68 (1.50-1.89)	2.41 (2.20-2.64)

Equipment-related injuries	1.52 (1.24-1.86)	1.13 (0.95-1.32)


Recurrence

Intrahepatic recurrence	222 (76.6%)

Extrahepatic recurrence	68 (23.4%)

Main treatment for recurrence

Transplantation	10 (3.4%)

Repeat resection	29 (9.8%)

Local ablation therapy	29 (9.8%)

TACE	172 (58.1%)

Chemotherapy	26 (4.3%)

Radiation therapy	16 (5.4%)

Cause of death

Recurrent HCC	182 (80.9%)

Complication of liver cirrhosis without recurrence	25 (11.1%)

Unrelated (including perioperative death)	18 (8.0%)


	Normoxic	Hypoxic	Hypoxic + CPP

Alkaline Phosphatase	179 <underline>+</underline> 20	195 <underline>+</underline> 31	176 <underline>+</underline> 16

ALT	25 <underline>+</underline> 4	30 <underline>+</underline> 10	33 <underline>+</underline> 6

AST	48 <underline>+</underline> 3	73 <underline>+</underline> 8 *	81 <underline>+</underline> 8 *

Creatine Kinase	163 <underline>+</underline> 46	236 <underline>+</underline> 90	225 <underline>+</underline> 38

GGT	2.0 <underline>+</underline> 0.0	3.0 <underline>+</underline> 0.0	2.4 <underline>+</underline> 0.6

Albumin	2.9 <underline>+</underline> 0.1	2.9 <underline>+</underline> 0.2	2.8 <underline>+</underline> 0.1

Total Protein	5.6 <underline>+</underline> 0.2	5.2 <underline>+</underline> 0.2	5.0 <underline>+</underline> 0.1

Total Bilirubin	0.1 <underline>+</underline> 0.0	0.1 <underline>+</underline> 0.0	0.1 <underline>+</underline> 0.0

Blood Urea Nitrogen	18.8 <underline>+</underline> 2.8	26.3 <underline>+</underline> 8.4	20.0 <underline>+</underline> 2.2


Parameters	Present study	Verkerk et al. [16]	Tüysüz et al. [15]

Ind IV:3	Ind IV:4

Gender	M	M	3F/2M	3F/1M

Age at last examination (y.)	14	12	1.5/21/22/23/24	2.5/10.5/11/17

Head circumference	−2SD	−2SD	−1 to −2.5 SD	−2 to −4 SD

Height (cm)	157	137	NA	NA

Intellectual disability	Severe	Severe	Severe in 5/5	Severe in 3/4

Seizures	+	-	-	+

Shy character	-	-	+	+

Aggressive behavior	+	+	-	-

Stereotype laughter	-	-	+	+

Severe speech disorder	+	+	+	+

Infantile hypotonia	+	+	+	+

Hypertonia	+	+	+	+

Hyperreflexia	+	+	NA	NA

Babinski sign	+	+	+	NA

Spasticity	+	+	+	+

Club feet	-	-	+	+

Independent walking (y.)	2	4	-	+/−

Ambulation	-	-	-	-

Craniofacial features

Facial hypotonia	-	-	NA	+

Bitemporal narrowing	-	-	NA	+

Broad nasal bridge	-	-	NA	+

Bulbous nose	-	+	NA	+

Short philtrum	+	+	NA	+

Brain MR imaging	Yes	No	3/5	4/4

Widened lateral ventricles	+		+	+

Thin splenium of the CC	+		+	+

Cerebellar hypoplasia/atrophy	+		2/3	-


Characteristic	Value	%

Age (years)

Range	30–87

Mean ± SD (range)	60.3±15.9

Gender, n

Male	62	51.2

Female	59	48.8

Diagnosis method, n

Histological diagnosis	78	64.5

Imaging and medical history diagnosis	43	35.5

Tumor type, n

Colorectal cancer	52	43.0

Lung cancer	19	15.7

Breast cancer	14	11.6

Renal cancer	7	5.8

Gastric cancer	5	4.1

Other	24	19.8

Tumor loading, n

With	72	59.5

Without	49	40.5

Adjuvant radiotherapy and/or chemotherapy, n

With	71	58.7

Without	50	41.3


Code	Test	Supported draft

INV_1_24	FISH/int	UMD (85%)

INV_1_53.3	FISH/int	UMD (94%)

INV_4_7.2	FISH/int	UMD (90%)

INV_7_103.2	FISH/int	UMD (96%)

INV_10_59.3	FISH/int	UMD (95%)

INV_14_32	FISH/int	UMD (73%)

INV_20_0	FISH/int	UMD (98%)

INV_23_0	FISH/met.	UMD

INV_26_18.8	FISH/int	UMD (75%)

INV_27_42.3	FISH/int	UMD (90%)

MDP_4_16.2	FISH/int	Btau (98%)

MDP_5_9.6	FISH/met.	UMD

MDP_7_7.6	PCR	UMD

MDP_7_43.1	PCR	-

MDP_28_0.7	PCR	UMD

DCM_2-11	FISH/met	UMD

DCM_3-13	FISH/met	Btau

DCM_3-2	FISH/met	UMD

DCM_3-22	FISH/met	UMD

DCM_7-X	FISH/met	UMD

DCM_10-1	FISH/met	UMD

DCM_10-4	FISH/met	UMD

DCM_15-X	FISH/met	UMD

DCM_27-21	FISH/met	Btau


Process Type	processes	instances	Time	Total ($)

Blast	21945	100	40 hours 0 mins	$ 3,680

Ortholog Estimation	281160	100	28 hours 21 mins	$ 2,622


	Odds ratio	95% Confidence interval	P value

Predictors of AKI

Log angiopoietin-2	4.41	2.02–9.63	<0.0001

Log osteoprotegerin	1.98	1.02–3.82	0.043

Agea	1.07	1.04–1.10	<0.0001

Predictor of severe malaria

Log angiopoietin-2	5.35	2.01–14.25	0.001

Log osteoprotegerin	2.66	1.15–6.14	0.022

Log parasite count	1.47	1.15–1.89	0.002


Pathway	TF	miRNA

Activin	TP53	miR-143

AKT	MYC	miR-145

ALK	GATA4	miR-187

ATM	SMAD1	miR-296

BMI1	ESRRB	miR-301

BMP	SOX2	miR-21

Cell cycle	NANOG	let-7a

EGF/EGFR	KLF4	miR-371

ERBB2	MYB	miR-372

ERK	MYCN	miR-373

FGF	ZFX	miR-367

Glycolysis	STAT3	miR-302a

Hippo	ZIC3	miR-302a*

IGF	ZFP42	miR-302b

JAK/STAT	SALL4	miR-302b*

c-KIT	REST	miR-302c

Lefty	TCF3	miR-302c*

LIF	HOXB1	miR-302d

MAPK	HAND1	miR-200c

MEK/ERK	POU5F1	miR-222

NF-κB	SRY

NHEJ/HR a	TBX5

Nodal	E2F4

Notch	GATA6

p53	PAX6

PRC2	TCF4

PDGF	FOXD3

PI3K	CNOT3

PTEN	ZEB2

RAS	ESX1L

RTK

Hedgehog (SHH)

Smad

Stat3

Telomerase

TGFβ

VEGF

WNT


Parameter	Shams	Exposure to AO nanowhiskers for:

2 wks	4 wks

Total cells/mouse, n x 103	74.0 ± 7.9	171.6 ± 19.7 **	440.3 ± 33.6 ***

Total protein, μg/mL	107.7 ± 4.7	108.0 ± 1.5	101.2 ± 2.7

LDH activity, U/L	180 ± 18	146 ± 17	191 ± 10


Gram	Bacterial strain	Concentration of SS-capped AgNPs (mM)	MIC (mM)

 	 	0.001	0.004	0.008	0.017	0.034

+	MRSA	T	T/C	C	C	C	0.008

+	S. aureus	T	T/C	C	C	C	0.008

+	B. subtilis	T	T/C	C	C	C	0.008

−	P. aeruginosa	T	C	C	C	C	0.004

−	A. baumannii	C	C	C	C	C	0.001

−	E. coli	T	C	C	C	C	0.004


	TCPC (n = 6)	TCPC + AVR (n = 4)

Morphology of AV valve

 SAVV (morphologically tricuspid valve)	5 (83 %)	0

 CAAV	1 (17 %) early death	4 (100 %)

Degree of AV valve regurgitation

 Slight	3 (50 %)	0

 Mild	3 (50 %)	0

 Moderate	0	2 (50 %)

 Severe	0	2 (50 %)

Early mortality	1	0


Patient	1	2	3	4

Age at onset (y)	6	1	0.8	2

Age at diagnosis* (y)	10	6	11	5

Present age (y)	13	8	15	Died at 8 Y

Family history	+	+	-	-

First symptom	Septicemia	Otitis media	Otitis media	Otitis media

Otitis media	+	+	+	+

Sinusitis	+	-	+	-

Pneumonia	+	+	+	+

Bronchiectasis	+	-	+	-

Arthritis	+	-	-	+

Skin infection	+	+	-	-

Septicemia	+	+	+	+

Meningitis/encephalitis	+	-	+	-

Recurrent diarrhea	-	-	-	+

Tonsils	Absent	Hypoplastic	Absent	Hypoplastic

Duration of IVIG treatment (m)	25	17	33	12


Gene Set	Number of Genes	Categorized Genes	p-Value

Galactose metabolism	16	Gck	<0.0001

Cysteine metabolism	16	Sult1c2	0.003

Aminoacyl-tRNA biosynthesis	16	Vars2	0.009

Wnt signaling pathway	112	Sox17Dkk2 *	0.014

Taste transduction	29	Gnat3 *Tas2r114	0.046

C21-Steroid hormone metabolism	10	Cyp21a1	0.1250

Chondroitin sulfate biosynthesis	14	B3gat2Chst12	0.1260

Antigen processing and presentation	58	RT1-Aw2	0.163


Primer	Forward	Reverse

IFN-γ	GGTCAACAACCCACAGGTCC	CGACTCCTTTTCCGCTTCC

IL-4	TCTCGAATGTACCAGGAGCCATATC	AGCACCTTGGAAGCCCTACAGA

IL-10	GCTCCTAGAGCTGCGGACT	TGTTGTCCAGCTGGTCCTTT

IL-17A	AGGACGCGCAAACATGAGTC	TTGGACACGCTGAGCTTTGAG

TGF-β	CTGGATACCAACTACTGCTTCAG	TTGGTTGTAGAGGGCAAGGACCT

Foxp3	ACACCCAGGAAAGACAGCAAC	CTCGAAGACCTTCTCACAACCAG

GAPDH	CAACTTTGGCATTGTGGAAGG	ACACATTGGGGGTAGGAACAC


Aspects	Score/question

1. Risk factors associated with obstetric fistula	1

 - Early pregnancy	0.125

 - Home delivery	0.125

 - Female Genital Mutilation	0.125

 - Evil spirits	0.125

 - Breach of a prohibited act	0.125

 - Prolonged labour	0.125

 - Bad luck	0.125

 - Malnutrition of the mother	0.125

2. Symptoms of obstetric fistula	1

 - Urinary incontinence	0.2

 - Faecal incontinence	0.2

 - Continuous sleeping	0.2

 - Stomach ache	0.2

 - Vulva irritation	0.2

3. Duration of normal labour	1

4. Source of emergency obstetric care	1

Total	4


	sense	antisense

#1	GTATCTGCACTCTCAATCAGGAGC	AAACTGTAACCCCTATCTCTACTCAC

#2	CCTGGGTTTCCACCATATGCTTTC	AGTTCCTTGCACTCCTGTTAACAA

#3	CCTGGGTTTCCACCATATGCTTTC	GGTCGCCTAGTGTCATGACCA

#4	GACCACATCCCAACCGAATC	CACAGGCCAGACTGACACCC

#5	GACCACATCCCAACCGAATC	CTGACACCCAGTAGTGAAGG

#6	GATAGCAGCCGCAGAAGAGC	CCACCTGGGTTTCCACCATA


Commercial laboratory variable	Mean change younger cohort	Mean change older cohort	p-value

CD3%	−2.75	2.33	0.036

CD4%	−2.50	1.67	0.028

WBC	2.13	−0.70	0.031

IgA	4.25	−13.17	0.059

Zinc/Copper Ratio	−0.08	0.13	0.061


Strain	Source	Accession no.	Genome size (bp)	N50 (bp)	No. of scaffolds (>300 bp)	G+C content (%)

Arcobacter sp. AF1028	Human feces	JART00000000	2,414,790	148,259	46	27.24

Arcobacter sp. AF1078	Human feces	JARS00000000	2,496,885	127,252	53	27.18


	All articles (n=168)	Including NEJM protocols (n=61)

Characteristics	n (%)	n (%)

Journal

 NEJM	61 (36)	61

 Lancet	64 (38)

 JAMA	19 (11)

 BMJ	8 (5)

 Annals of Internal Medicine	5 (2)

 PLoS Medicine	7 (4)

 Archives of Internal Medicine	2 (1)

 JAMA of Internal Medicine	2 (1)

Year of publication

 2010	26 (15)	9 (15)

 2011	27 (16)	9 (15)

 2012	29 (17)	8 (13)

 2013	39 (23)	19 (31)

 2014	27 (16)	10 (16)

 2015	20 (12)	6 (10)

Type of intervention

 Drug	112 (67)	44 (72)

 Surgery	22 (13)	7 (11)

 Other	34 (20)	10 (16)

Randomisation

 Patient	163 (97)	59 (97)

 Cluster	5 (3)	2 (3)

Power

 80%	6 (36)	19 (31)

 85%	11 (7)	5 (8)

 90%	65 (39)	26 (43)

 71–99% (excluding the above)	21 (12)	11 (18)

 Not reported/unclear	10 (6)	0

Composite outcome

 Yes	78 (46)	37 (61)

 No	90 (54)	24 (39)

Disease

 Heart disease	30 (18)	13 (21)

 Blood disorder	19 (11)	6 (10)

 Cancer	16 (10)	8 (13)

 Diabetes	11 (7)	2 (3)

 Thromboembolism	6 (4)	6 (10)

 Skin infection (non-contagious)	3 (2)	2 (3)

 Urinary tract infection	3 (2)	0

 Arthritis	3 (2)	1 (2)

 Opthomology	3 (2)	1 (2)

 Pneumonia	3 (2)	1 (2)

 Complications in pregnancy	3 (2)	0

 Stroke	3 (2)	2 (3)

 Testing method	3 (2)	1 (2)

 Appendicitis	2 (1)	1 (2)

 Depression	2 (1)	0

 Other non-infectious disease	18 (11)	7 (11)

 HIV	18 (11)	2 (3)

 Tuberculosis	6 (4)	4 (7)

 Malaria	4 (2)	1 (2)

 Skin infection (contagious)	2 (1)	0

 Hepatitis C	2 (1)	2 (3)

 Other infectious disease	8 (5)	1 (2)


Author	Study design	Oral health criteria	Study population	Results

Bundgaard et al. (85)	Case-control	Missing teeth	161 patients and 400 controls (Denmark)	Significantly increased risk of developing oral SCCA for patients with fewer than 15 teeth

Rezende et al. (86)	Case-control	CPITNa and DMFTb	50 patients and 50 controls (Cuba)	76% of subjects in cancer group showed greater than 6 mm pockets compared to 10% of control group

Garrote et al. (87)	Case-control	Missing teeth	200 patients and controls (Cuba)	Significantly increased risk of oral cancer for patients missing 16 or more teeth

Hiraki et al. (88)	Case-control	Missing teeth	429 patients and 10,480 controls (Japan)	Significantly increased risk of head and neck cancer with decreased number remaining teeth

Marshall et al. (89)	Case-control	Missing teeth	290 patients and controls (United States)	Significantly increased risk of oral cancer with loss of 11 or more teeth

Michaud et al. (90)	Cohort	Self-reported history of periodontal disease (confirmed by radiographs and missing teeth)	118 patients (United States)	No significant increase in risk for oropharyngeal cancer with history of periodontal disease or increased number of tooth loss

Rosenquist et al. (91)	Case-control	Missing teeth	132 patients and 320 controls (Sweden)	Significantly increased risk of oral and oropharyngeal cancer for missing over 20 teeth

Tezal et al. (92)	Cohort	Clinical attachment loss (CAL)	131 oral tumors and 323 oral pre-cancerous lesions (United States)	Significantly increased risk of oral tumor and pre-cancerous lesion with >1.5 mm clinical attachment loss

Tezal et al. (81)	Case-control	Alveolar bone loss	51 cases and 54 controls (United States)	Significantly increased risk of tongue cancer with increased alveolar bone loss

Tezal et al. (82)	Case-control	Alveolar bone loss	266 patients and 207 controls (United States)	Significantly increased risk of oral cavity SCC with periodontitis

Tezal et al. (93)	Case-control	Alveolar bone loss	124 head and neck SCC patients (United States)	Periodontitis is associated with tumor HPV status

Wen et al. (94)	Cohort	Medical records from insurance claims	96,375 gingivitis and 51,791 periodontitis cases (Taiwan)	Significantly increased risk of oral cancer with the history of periodontitis

Zheng et al. (95)	Case-control	Missing teeth	404 subjects and controls (United States)	Significantly increased risk of oral cancer with increased missing teeth


Characteristic	Patients (n= 19)(%)

Sex (males/females)	12/7

Age, years, median (range)	54 (30–75)

Underlying liver disease

Hepatitis B virus	11 (57.89)

Alcoholic	3 (15.79)

Autoimmune hepatitis	1 (5.26)

Hybrid cause	4 (21.05)

Basic underlying disease

Cardiovascular disease	4 (21.05)

Diabetes mellitus type 2	2 (10.53)

Chronic lung diseases	2 (10.53)

Complications

Hepatic encephalopathy	8 (42.10)

Hepatic renal syndrome	4 (21.05)

Upper gastric bleeding	4 (21.05)

Ascites	16 (84.21)

Hydrothorax	10 (52.63)

Hepatic carcinoma	2 (10.53)

CTP scores (mean ± SD)	11 ± 2

Child B	6 (31.58)

Child C	13 (68.42)

MELD (mean ± SD)	22 ± 7

Neutropenia	2 (10.53)

Broad-spectrum antibiotics usage	18 (94.74)

One antibiotic	9 (47.37)

Two antibiotics	4 (21.05)

Three antibiotics	5 (26.32)

Steroids exposure(longer than 1 week)	11 (57.89)

Survival rate

1 month	5/19

3 month	4/19


	Mean	Median	Min	Max

% of Patients Who Should Receive DES, 1st Year Following Approval

Bare metal stent patients	42.8%	30.0%	5.1%	100.0%

CABG patients	16.8%	10.0%	5.0%	50.0%

% of Patients Who Should Receive DES, 2nd Year Following Approval

Bare metal stent patients	56.0%	50.0%	10.2%	100.0%

CABG patients	25.5%	20.0%	5.0%	80.0%

% of Patients Who Should Receive DES, 3rd Year Following Approval

Bare metal stent patients	70.1%	90.0%	30.0%	100.0%

CABG patients	31.4%	30.0%	5.0%	90.0%

% of Patients Who Should Receive DES, 4th Year Following Approval

Bare metal stent patients	79.7%	90.0%	40.6%	100.0%

CABG patients	37.8%	35.0%	5.0%	90.0%

% of Patients Who Should Receive DES, 5th Year Following Approval

Bare metal stent patients	86.8%	90.0%	60.8%	100.0%

CABG patients	43.7%	40.0%	5.0%	90.0%


Job satisfaction domains	Level of satisfaction

Satisfied	Dissatisfied

N (%)	N (%)

Leadership and planning	175 (43.2)	230 (56.8)

Culture and communications	180 (44.6)	225 (55.4)

Employee’s role	211 (52.1)	194 (47.9)

Work environment	178 (43.9)	227 (56.1)

Relationship with supervisor	163 (40.2)	242 (59.8)

Training and development	165 (41.4)	237 (58.6)

Pay and benefits	148 (36.5)	257 (63.5)

Coworker relation ship	209 (51.6)	196 (48.4)

Overall satisfaction	179 (44.2)	226 (55.8)


Outcomes	Support (N = 105)	Control (N = 107)	RR (95%CI)	p value

Apgar score at 1 minute < 7	20	21	0.97 (0.56–1.68)	0.915

Apgar score at 5 minutes < 7	3	2	1.53 (0.26–8.96)	0.681*

Birthweight (g) (mean ± SD 95%)	3.197 (2.360–4.245)	3.246 (2.410–4.145)	-	0.370¶

Admission to NICU	5	6	0.91 (0.47–1.77)	0.781

Immediate contact mother/newborn	52	41	1.29 (0.95–1.76)	0.100

Time of contact mother/newborn (min) (mean ± 95% SD)	25.1 (10–55)	22.7 (10–40)	-	0.360†

Takes breast/suckles in delivery room	12	7	1.75 (0.72–4.26)	0.213

Takes breast/suckles (12 h following birth)	99	100	1.08 (0.59–1.97)	0.801

Breast fissure	7	6	1.19 (0.41–3.42)	0.747

Number of breast-feeds 12 hours following birth (mean)	4.3 (0–12)	4.4 (0–10)	-	0.589†


Risk factor	Intervention options if risk factor identified

History of falls/falls injuries	Referral to GPAppropriate acute management if injury recent

Medications (number)	Refer to GP for medication review

Medications (associated with increased falls risk)	Refer to GP/specialist for medication review

Medical conditions (associated with increased falls risk)	Refer to GP/specialist for review

Sensory loss: vision	Brochure on lighting and home safetyRefer to optometristRefer to Ophthalmologist via GPRefer to Vision Australia (includes mobility training and aids for visually impaired)Refer to OT for home assessmentRefer to GP

Sensory loss: hearing	Refer to audiologist

Sensory loss: somatosensory	Refer to podiatristRefer to GP

Feet and footwear	Refer to podiatristProvide information about good footwear and falls prevention

Cognitive status	Refer to GPMemory Clinic referral in consultation with GP if memory problems have not been investigatedReferral to OT for strategies to facilitate memory and/or home assessment

Continence	Refer to GPContinence clinic referralRefer to physiotherapistRefer for OT home assessment/functional assessment, including need for commode

Nutritional status	Provide brochure on nutritionRefer to dieticianGP referral

Environment	Provide with information pamphlet on safety in the homeRefer for OT home assessment/functional assessment and training

Function	Refer to OT for home assessment/functional assessment and trainingRefer to Physiotherapist for assessment and exercise to improve functionReferral for support services

Functional behaviour	Refer to physiotherapist, OT, GP

Balance	Home exercise programReferral to PhysiotherapistReferral for OT for a home assessmentReferral to GP for further investigation

Gait and physical activity	Home exercise programReferral to PhysiotherapistReferral for OT home assessment/functional assessment and trainingBrochure on tips for walking

Osteoporosis risk	Refer to GP for consideration of calcium and/or vitamin D supplementsRefer to dieticianHip protectors

Additional options for preventing falls injury	Hip protectorsPersonal alarm


Patient #	Sex	Age(year)	Injected activity (MBq)	Diagnosis

1	M	2	320	Mediastinum 7-cm diameter NET

2	F	7	450

3	M	11	490	Right adrenal pheochromocytoma (only shown in SPECT/CT image)

4-Aa	F	12	500

5	F	12	600

4-Ba	F	13	450

6	F	13	480	Appendix NET, area of accumulation above the uterus

7	F	14	600	MEN-1, head of the pancreas NET and lymph node accumulation on the left side

8	M	14	940

9	F	16	500

10	F	16	600

11	M	17	720	MEN-1, head of the pancreas insulinoma


Cell line	Media	Comment

1. 293	DMEM	Embryonic kidney

2. A549	DMEM	Adenocarcinomic alveolar basal epithelial

3. C33a	DMEM	Cervical carcinoma

4. DUT145	DMEM	Prostate cancer

5. H1229	RPMI	Lung carcinoma

6. HaCAT	RPMI	Immortalized, non-tumorigenic keratinocyte

7. HCT116	McCoy 5A	Colorectal carcinoma

8. HeLa	Joklik	Cervical carcinoma

9. hESC2	DMEM	Human embryonic stem cells

10. HFF	DMEM	Human foreskin fibroblasts

11. HL60	IMM	Promyelocytic leukemia cells

13. Huh7.0	DMEM	Hepatocarcinoma

14. Huh7.5	DMEM	Hepatocarcinoma (RIG-I-deficient)

14. MCF7	DMEM	Breast carcinoma

15. MDaMB231	L15	Breast carcinoma

16. Mdm13	DMEM	Monocyte-derived macrophages

17. NB4	RPMI	Acute promyelocytic cell line

18. PANC1	DMEM	Pancreatic carcinoma, epithelial-like

19. PC3	DMEM	Prostate cancer

20. SAOS	McCoy 5A	Epithelial-like osteosarcoma cell line

21. SW480	L15	Colon adenocarcinoma

22. U2OS	DMEM	Osteosarcoma

23. U251	DMEM	Glioblastoma

24. U937	RPMI	Leukemic monocyte lymphoma


Gene abbreviationa	Gene symbola	Accession no.b	Gene description	Gene group	Z-Testc	Ratiod	95% CIe

Up-regulated gene expression

 TECK/CCL25	Scya25	NM_009138	small inducible cytokine A25	Chemokine	1.5 × 10–14	4.2	6.2–2.9

 Mdk	Mdk	NM_010784	midkine	Neurotrophic group	2.9 × 10–7	3.0	4.7–1.9

 IL-5	Il5	NM_010558	interleukin 5	Interleukin	9.5 × 10–4	1.9	2.9–1.3

 VEGF-A	Vegf	NM_009505	vascular endothelial growth factor	Angiogenic factor	2.5 × 10–5	1.8	2.2–1.4

Down-regulated gene expression

 EphA3	Epha3	M68513	eph-related receptor tyrosine kinase (Mek4)	Eph family	4.0 × 10–8	0.5	0.6–0.4

 CCR-4	Cmkbr4	NM_009916	chemokine (C-C) receptor 4	Chemokine receptor	1.8 × 10–5	0.6	0.8–0.5

 LIF	Lif	NM_008501	leukemia inhibitory factor	Cytokine and receptors	3.0 × 10–5	0.6	0.8–0.4

 GDF-7	Gdf7	U08339	BALB/c putative growth factor GDF7 (Gdf7) gene	TGF-beta superfamily	2.4 × 10–4	0.5	0.7–0.3

 EBF	Ebf	NM_007897	early B-cell factor	Signal transduction	3.7 × 10–4	0.5	0.7–0.4

 CD27/TNFRSF7	Tnfrsf7	L24495	CD27 antigen	TNF superfamily	6.4 × 10–4	0.6	0.8–0.4

 SLIT-3	Slit3	AF088902	SLIT1 protein	Developmental factor	9.2 × 10–4	0.7	0.8–0.5

 CX3CL1	Scyd1	NM_009142	small inducible cytokine subfamily D, 1	Chemokine	1.2 × 10–3	0.4	0.7–0.2

 SMAD1	Madh1	NM_008539	MAD homolog 1 (Drosophila)	Signal transduction	1.3 × 10–3	0.6	0.8–0.5

 A1	Bcl2a1a	L16462	hemopoietic-specific early response protein	Apoptosis related	1.5 × 10–3	0.6	0.8–0.4


Organization	Country	Title	Year

National Institute of Health Care and Excellence	United Kingdom	Recognition, referral, diagnosis, and management of adults with autism	2012

Australian Psychological Association	Australia	Clinical Assessment Resource: An overview of best practice tools and approaches to conducting biopsychosocial and developmental assessment of child, young people, and adults with a disability who display behaviors of concern	2011

Canadian Association of Occupational Therapists (CAOT)	Canada	Position Statement on Autism Spectrum Disorders and Occupational Therapy	2015

American Occupational Therapy Association (AOTA)	United States	Scope of Occupational Therapy Services for Individuals with ASD across the Life Course	2015

College of Occupational Therapy	United Kingdom	Occupational Therapy and Learning Disabilities	2012


Coefficients of variation (CVs)	Children groups	ANOVA

	Spastic CP (n =10)	TD (n =10)	F1,18	p value	Effect size d

Utterance duration

 Mono-syllable task	17.87 ± 11.87	5.23 ± 2.33	10.923	0.004*	0.615

 Poly-syllable task	24.30 ± 17.90	7.57 ± 4.11	8.299	0.010	0.562

Peak vertical oral opening displacement

 Mono-syllable task	24.34 ± 13.53	34.14 ± 26.16	1.108	0.307	0.241

 Poly-syllable task	18.30 ± 15.82	29.42 ± 20.20	1.880	0.187	0.308

Peak vertical oral opening velocity

 Mono-syllable task	17.21 ± 14.97	24.69 ± 13.50	1.376	0.256	0.266

 Poly-syllable task	15.63 ± 17.09	15.16 ± 18.78	0.003	0.954	0.014


	Blastn (WGS An. gambiae)	Blastx (Nr)	Blastn (Nr)	Blastn (dbEST)	Unannotated	Total

3 Positive Controls	No Significant Hit	3				3

403 Unique Transcripts	403	240	8	112	43	403

Early Genes	144	77	2	45	20	144

Middle Genes	130	78	6	36	10	130

Late Genes	139	93	2	31	13	139

Total	413	248	10	112	43	413


Study	Bacterial strain	Preparation	Patient population	Intervention	Results

 	 	 	Cell or animal type

In vitro experiments

 Strunk et al.,78 2012	SE 1457	Heat-killed	GA<30wk, 31-33 wk, 37-41 wk	6 h	IL-1β, IL-6, IL-8, TNF-α↑with GA

 	 	108cfu/ml	Cord & adult peripheral MNCs	 	Adult level TLR2 expression & phagocytosis

 Mohamed et al.,79 2007	SE PT 9657	Heat-killed	Healthy term infants	4 h	IL-1β, IL-6, IL-8, TNF-α↑with time

 	 	103cfu/ml	Cord & adult peripheral WBC	 	Pro-inflammatory effect: SE <E.coli & GBS

 Tatad et al.,80 2008	Clinical isolate	Heat-killed	Healthy term & preterm infants	 18 h	IL-6, IL-8, IL-10, IL-12↑ similar to adult

 	 	104cfu/ml	Cord & adult peripheral WBC	 	Inflammatory response: preterm > term

 Härtel et al.,81 2007	ATCC 12228	Live bacteria	Term & preterm infants	24 h	IL-6, TNF-α↑with GA

 	Strain 94B080	1cfu:1 WBC &	Neonatal peripheral WBC	 	Pro-inflammatory effect: BF+ strain<BF- strain

 	Strain 94B575	10 cfu:1 WBC	 	 	IL-10, TGF-β expression independent of GA

 Peoples et al.,82 2009	Clinical isolate	Heat-killed	Healthy term & preterm infants	18 h	IL-6, IL-10↑> adult

 	 	104 cfu/ml	Cord & adult peripheral WBC	 	IL-8, IL-12, INF-NK, INF-T↑ similar to adult

 	 	 	 	 	Inflammatory response: preterm=term

 Haase et al.,83 2011	ATCC 12228	Live bacteria	Healthy term & preterm infants	1 h	TNF-α, IL-6, IL-8↑

 	Strain 94B080	1cfu:1 WBC	Cord WBC	 	Pro-inflammatory effect: BF+ strain>BF- strain

 	Strain 94B575

 Björkqvist et al.,77 2004	Clinical isolate	Live bacteria	Healthy term & preterm infants	30 min	Oxidative burst intensity: preterm < term

 	 	10 cfu:1 PMNL	Neonatal peripheral PMNLs	 	SE similar to GBS

 Ivarsson et al.,104 2013	Clinical isolate	Live bacteria	Vascular endothelial cells	18 h	IL-8, ICAM-1 ↑

 	 	104cfu/ml	Small airway epithelial cells	 	Pro-inflammatory effect: SE > SA

 Hussain et al.,105 2013	Strain 94B080	Live bacteria	Bronchial epithelial cells	36 h	TNF-α, IL-6, IL-8 and iNOS↑ with time

 	 	104cfu/ml	 	 	Expression of ENaC and CFTR↑

In vivo experiments

 Kronforst et al.,87 2012	SE 1457	Live bacteria	C57BL/6 WT mice	48 h	At 2 h:

 	 	up to 2×109 cfu/ml	< 24 h old	 	IL-1β, IL-6, TNF-α, TLR2↑ with inoculum

 	 	 	 	 	At 24 h & 48 h:

 	 	 	 	 	Inoculum-dependent neonatal weight loss

 Bi et al.,86 2015	SE 1457	Live bacteria	C57BL/6J WT mice	72 h	At 6 h:

 	 	1×108cfu/ml	< 24 h old	 	IL-6, CCL2, CXCL1, IL-12↑ in blood & brain

 	 	 	 	 	Caspase-3 & TLR2 mRNA ↑ in the brain

 	 	 	 	 	At 24 h:

 	 	 	 	 	PMNLs↑ in blood & cerebral spinal fluid

 	 	 	 	 	White and grey matter impairment


Drug’s name	Dose	Comments

Vasodilator drugs (hypotensives)

Propofol	2 - 2.5 mg/kg load, 25 - 75 μg/kg/min maintain	Local irritation, propofol infusion syndrome

Remifentanil	1 μg/kg load, 0.05 μg/kg/min maintain	Respiratory depression, hyperalgesia, vomiting

Dexmetedomidine	1 mg/kg load, 0.7 mg/kg/h maintain	Sedative effects

Nitroprusside	1 - 2 μg/kg/min	Severe hypotension, cyanide toxicity

Nitroglycerine	25 - 250 μg/min	Reflex tachycardia, methemoglobinemia

Nicardipine	5 mg/h	Braycardia, severe hypotension, cardiac blocks

Esmolol	5 - 10 mg/3 - 5 min bolus	AV block, bronchial hyperactivity

Labetalol	5 - 10 mg bolus

Urapidil	10 - 15 mg/h	Severe hypotension

Clonidine	0.1 - 1.2 mg	Rebound hypertension, dry mouth

Magnesium sulfate	1 - 8 mg load, 1 - 4 mg/h maintain	Potentiates muscle relaxants

Vasoconstrictor drugs (hypertensives)

Epinephrine	1 - 20 μg/min	Tachycardia

Norepinephrine	1 - 30 μg/min	Reflective bradycardia

Dopamine	5 - 10 μg/min	Tachycardia, arrhythmias

Phenilephrine	10 - 100 μg/min	Reflective bradycardia

Vasopressin	0.1 - 0.4 units/min	Myocardial infarction

Ephedrine	5 - 10 mg	None


Intervention	At Risk Target Population	Numbers at Risk Reached	% of Identified at Risk Reached by the RED Strategy	General Target Population in RED Catchment Areas	% of Additional Population Reached through the RED Strategy

Additional immunized children	489	477	97.55	3126 (children 1-15)	15% of the target children for immunization

Additional registered populations at Family Group Practices clinics	2598	2485	95.65	8708(Total Population in RED Area)	28.5% of total registered population at the family clinics

Additional ANC care contacts	515	508	98.64	5616(Total ANC Contacts in RED Area)	9% of all ANC Contacts

Additional family planning contacts	1047	1047	100.00	96560(Total Family Planning Contacts in RED Area)	1.08% of all family planning contacts

Additional emergency food provision	Not yet fully assessed	515	Not yet fully assessed	8708(Total Population in RED Area)	5.9% of Target population


Composition	CAS	RP-A	RP-E

Moisture	9.7	9.8	10.9

Protein	87.3	86.4	79.6

Carbohydrate	0.2	0.9	2.5

Lipids	0.5	0.8	0.8

Ash	1.7	1.0	1.5

Dietary fiber	0.6	1.1	4.7


Design	Intervention	Country	Focus	Sample	Sample size(n)	Duration	Reference

Cluster blind RCT	Electronic decision support system	USA	GP	T1D, T2D	639	21 months	[15]

Cluster RCT	Diabetes register	UK	GP	T2D	3, 608	15 months	[16]

Cluster RCT	Diabetes register	USA	GP	T2D	7, 101	12 months	[17]

Cluster RCT	Electronic telemedicine	USA	Patient	T2D	1, 665	12 months	[18]

Cluster RCT	Electronic telemedicine	USA	GP	T2D	1, 665	12 months	[19]

Cluster RCT	Electronic self-management system	USA	Patient	T2D	886	12 months	[20]

RCT	Electronic self-management system	USA	Patient	T1D, T2D	122	6 months	[21]

RCT	Electronic self-management system	USA	Patient	T1D, T2D	104	12 months	[22]

RCT	Electronic self-management system	USA	Patient	T1D, T2D	62	6 months	[23]

Nonrandomised cluster control trial	Electronic management system	USA	GP	T1D, T2D	6, 646	24 months	[24]

Nonrandomised control trial	Diabetes register	USA	GP	T1D, T2D	898	20 months	[25]

Nonrandomised control trial	Personal Digital Assistant (PDA) based electronic management system	USA	GP	T2D	173	16 months	[26]

Nonrandomised control trial	Diabetes register	USA	GP	T1D, T2D	661	2 years	[27]

Nonrandomised control trial	Electronic decision support system	USA	GP	T1D, T2D	16	6 months	[28]

Single sample before and after design	Diabetes register	USA	GP	T1D, T2D	62	3 years	[29]

Single sample before and after design	Diabetes register	Korea	GP	T1D, T2D	185	3 months	[30]


 	Amplitude of extension reflex score < 2.5	Rotarod time on rod < 90 s	Symmetry of extension reflex score < 1	Stride length < 5 cm

hA30Pα-syn+/+	18.1 ± 0.2 months	19.3 ± 0.2 months	20.0 ± 0.2 months	20.7 ± 0.2 months

parkin+/-; hA30Pα-syn+/+	18.4 ± 0.2 months	20.2 ± 0.2 months	22.3 ± 0.2 months	23.0 ± 0.2 months

parkin-/-; hA30Pα-syn+/+	21.0 ± 0.2 months	23.2 ± 0.2 months	23.4 ± 0.2 months	> 24 months


	%

	Arthritis	Stroke	Angina	Diabetes	Lung disease	Asthma	Depression	Cataracts

No hypertension	18.30	1.13	5.85	4.55	3.33	3.16	3.76	2.78

Hypertension diagnosed and measured	35.61	8.91	6.25	21.44	4.02	7.35	3.63	8.92

Hypertension measured but not diagnosed	18.83	2.24	3.43	4.32	1.54	3.05	1.40	1.18

Normal blood pressure but diagnosed with hypertension	38.90	3.91	12.32	15.65	7.72	14.43	7.55	12.56


Outcome	Impact of Statins on rate of events modeled using Cox Proportional Hazards (HR, 95% CI) (Statin versus No Statin)	Impact of Statins on number of events, modeled using Generalized Linear Models (RR, 95% CI) (Statin versus No Statin)

All-cause re-hospitalizations

Modeled without propensity score	0.84 (0.78-0.90)	0.97 (0.90-1.04)

Modeled with propensity score	0.98 (0.91-1.06)	1.04 (0.97-1.12)

CVD re-hospitalizations

Modeled without propensity score	0.98 (0.90-1.07)	0.90 (0.86-1.12)

Modeled with propensity score	1.11 (1.02-1.22)	1.03 (0.92-1.16)

All physician visits	N/A

Modeled without propensity score		0.84 (0.79-0.88)

Modeled with propensity score		0.97 (0.92-1.02)

CVD-related physician visits	N/A

Modeled without propensity score		1.18 (1.09-1.29)

Modeled with propensity score		1.34 (1.23-1.46)

Coronary Revascularizations		N/A

Modeled without propensity score	1.55 (1.30-1.84)

Modeled with propensity score	1.15 (0.97-1.36)

Mortality		N/A

Modeled without propensity score	0.41 (0.35-0.49)

Modeled with propensity score	0.74 (0.63-0.88)


Variable	Mean (SD)	P-value

Material	CEM cement	68* (28)	0.92

MTA	67 (39)

Subgroups	AP+GP	55 (28)	0.005

AP+TO	67 (14)

Obturation with AP material	56 (29)

Unfilled	96 (37)


Author	GA at diagnosis (weeks)	Treatment	Complications	Follow-up (months)	Outcome

Benedetto et al.	9	Endoscopy with HCPs	no	1	Normal

Chen et al.	31	Endoscopy with HCPs	HELLP syndrome	2	Normal


GBR	Auto only	Auto + xeno	Xeno only	Syn only	Total

No	40	44	79	17	180

%	22.2	24.4	43.9	9.4	100.0


Variable	Biliary acute Pancreatitis (n = 425)	Hypertriglyceridemia acute Pancreatitis (n = 305)	P value

Hospital mortality, no.	36(8.5%)	24(7.9%)	0.787

Need of surgery, no.	39(9.2%)	33(10.8%)	0.529

ICU admission	260(61.2%)	186(61.0%)	1

Length of ICU stay, days	4(2,12)	4(2,10.5)	0.975

Length of hospital stay, days	9(4,22.5)	9(5,23)	0.58

Cost, Thousand CHY	48.7(22.8157.8)	51.0(27.9134.6)	0.623


Drug	Disease/disturbance	Side effect

Cefradine	Urinary tract infection	Hypersensitivity, elevated liver enzyme, diarrhea

Nitroxoline	Urinary tract infection	Gastrointestinal intolerance, urine coloration

Sulfonamide	Urinary tract infection	Hypersensitivity, folic acid deficiency, hematological abnormality

Levofloxacin	Urinary tract infection	Diarrhea, tendinitis, seizure neuropathy, elevated liver enzyme

Atenolol	Hypertension	Bradycardia, cough, Raynaud's syndrome

Amlodipine	Hypertension	Flush, tachycardia, edema

Solantin	Thromboembolism	Dizziness, abdomen distress, angina, headache

Ursodeoxycholic acid	Liver cirrhosis	Gastrointestinal disturbance

Atorvastatin	Hyperlipidemia	Gastrointestinal disturbance, elevated liver enzyme, myopathy, neuropathy

Chinese herb drugs	Multiple somatic complaints	Unknown


Patient study code	Pre-study dopamine agonist	Trial arm	First IMP	Daily dose (mg)	Number of days on IMP	Second IMP	Daily dose (mg)	Number of days on IMP

PD1	RPR	1	PPX	2.1	3	RPRa, b	8	134

PD2	RPR	1	PPX	2.62	58	RPR	10	48

PD3	RPR	2	RPR	6	51	PPX	1.57	58

PD4	RPR	2	RPR	4	40	PPX	1.05	55

PD5	Consented but then withdrew before taking first IMP

PD6	PPX	1	PPX	2.1	64	RPR	8	52

PD7	PPX	2	RPR	10	13	PPXa, b	2.62	97

PD8	RPR	2	RPR	12	54	PPX	3.15	62

PD9	PPX	1	PPX	1.57	62	RPR	6	56

PD10	RPR	1	PPX	2.1	53	RPR	8	68

PD11	PPX	1	PPX	1.05	48	RPRb	4	30

PD12	PPX	2	RPR	10	52	PPX	2.62	56

PD13	Consented but then withdrew before taking first IMP

PD14	PPX	1	PPX	0.52	52	RPR	2	37

PD15	Consented but then withdrew before taking first IMP

PD16	PPX	1	PPX	1.57	63	RPR	6	55

PD17	PPX	2	RPR	6	60	PPX	1.57	37

PD18	PPX	2	RPR	6	3	Withdrew from IMP and study

PD19	RPR	1	PPX	2.1	55	RPR	8	84

PD20	PPX	2	RPR	8	66	PPX	2.1	41

PD21	PPX	1	PPX	3.15	100	RPRb	12	7

PD22	RPR	2	RPR	6	55	PPX	1.57	48

PD23	PPX	2	RPR	8	5	Withdrew from IMP and study

PD24	RPR	2	RPR	6	58	PPX	1.57	37

PD25	RPR	2	RPR	2	68	PPX	0.52	62


Parental feeding practices	Family breakfast frequency	Family dinner frequency	Family supper frequency

Monitoring	.11*	.04	.02

Child control	-.09**	-.11*	-.03

Encourage balance and variety	.06	.08**	.04

Environment	.13*	.09**	.12*

Involvement	.01	-.00	.02

Pressure to eat	.08**	.00	.01

Restriction for weight	-.01	-.04	-.02

Food as reward	-.02	-.09**	-.00

Restriction for health	-.05	-.06	-.05

Teaching nutrition	.10*	.06	.09**

Modeling	.11*	.06	.08**

Emotion regulation	-.02	-.08**	.01


Diagnoses	Patient count	% of Total

Pre-Index Period

Total Unique Patients in the Population	5,490

Patients with ≥ 1 Pertussis-like event	3,140	57

Acute Respiratory:	2,857	52

 COUGH	1,350	25

 UPPER RESPIRATORY TRACT INFECTION	1,004	18

 ACUTE BRONCHITIS	938	17

 ASTHMA	449	8

 ALLERGY	413	8

 LOWER RESPIRATORY TRACT INFECTION	387	7

 OTHER PNEUMONIA	313	6

Other :	1,798	33

 HYPERTENSION	579	11

 SHORTNESS OF BREATH	368	7

 HIGH CHOLESTEROL	316	6

 GERD	290	5

 CHEST PAIN	266	5

 COPD AND OTHER ALLIED CONDITIONS	229	4

 DIABETES	224	4

 LUMBAR STRAIN OR BACK PAIN	171	3

Post-Index Period

Total Unique Patients in the Population	5,490	100

Acute Respiratory:	5,053	92

 WHOOPING COUGH-UNSPECIFIED ORGANISM	2,224	41

 COUGH	2,222	40

 UPPER RESPIRATORY TRACT INFECTION	770	14

 ACUTE BRONCHITIS	694	13

 WHOOPING COUGH-BORDETELLA PERTUSSIS	605	11

 ASTHMA	551	10

 OTHER PNEUMONIA	468	9

 ALLERGY	404	7

 LOWER RESPIRATORY TRACT INFECTION	359	7

 PNEUMONIA IN WHOOPING COUGH	237	4

Other:	2,309	42

 HYPERTENSION	851	16

 HIGH CHOLESTEROL	495	9

 SHORTNESS OF BREATH	445	8

 DIABETES	421	8

 GERD	421	8

 COPD AND OTHER ALLIED CONDITIONS	388	7

 CHEST PAIN	300	5


Item	Experiment A [8]	Experiment B

Study design	Design: parallel crossover Diets: control (CON) and treatment (TRMT)Duration: 22 d with glucose kinetics assessed on day 19 of study 	Design: parallel crossoverDiets: control (CON) and treatment (TRMT)Duration: 63 d with glucose kinetics assessed on day 35 of study

Study population	A total of 6 neutered male Labrador Retrievers, 3-black-coated (3.9 yr; 27.3 kg) and 3-chocolate-coated (6.8 yr; 35.0 kg)	A total of 12 black Labrador Retrievers, 5 spayed females and 7 neutered males (27.0 ± 0.6 kg; 4.9 ± 0.2 yr of age)

Key details of glucose kinetics experiment	Isotope: U-13C-glucosePrime: 77.8 μmol/kgConstant: 0.136 μmol/min·kgFasting collections (18 h since last meal): 6 blood samples were taken at 60, 85, 110, 135, 160, and 185 min followed by 4 breath samples taken at 220, 245, 270, and 295 min after isotope infusion (start of isotope infused considered time 0) Postprandial collections: total food ration of 14 g/kg divided into 15 equal sized meals fed in 25 min intervals; 6 blood samples were taken at 60, 85, 110, 135, 160, and 185 min followed by 4 breath samples taken at 220, 245, 270, 295, 320, and 345 min after initial meal	Isotope: U-13C-glucosePrime: 8.1 μmol/kgConstant: 0.136 μmol/min·kgFasting collections (18 h since last meal): 6 fasting blood samples were taken at 90, 105, 120, 135, 150, and 165 min followed by 6 breath samples taken at 180, 205, 230, 255, 280, and 305 min after isotope infusion (start of isotope infused considered time 0)Postprandial collections: total food ration of 23 g/kg divided into 14 equal sized meals fed in 25 min intervals; 6 fasting blood samples were taken at 90, 105, 120, 135, 150, and 165 min followed by 6 breath samples taken at 180, 205, 230, 255, 280, and 305 min after initial meal.


Parameters	N = 506

Age in years, mean (SD)	23.8 (3.4)

Age categories

<20 yr, n (%)	10 (1.9)

20-29 yr, n (%)	454 (89.9)

≥30 yr, n (%)	41 (8.1)

Residence

Urban, n (%)	148 (29.2)

Rural, n (%)	359 (70.8)

Education

No schooling, n (%)	161 (31.8)

Primary, n (%)	136 (26.8)

Secondary, n (%)	173 (34.2)

Higher, n (%)	36 (7.1)

SES1 rank (quintiles) n (%)

1 – Poorest	117 (23.1)

2	107 (21.2)

3	112 (22.1)

4	85 (16.8)

5	85 (16.8)

Gravidity

Primigravidae, n (%)	216 (42.7)

Secundigravidae, n (%)	162 (32.0)

Gravidae-3, n (%)	73 (14.4)

Gravidae-4, n (%)	34 (6.7)

Multigravidae (≥5)2 n (%)	21 (4.2)

Used bednet previous night, n (%)	89 (17.8)

ITN (any), n (%)	1 (0.2)

Used any drug to prevent malaria, n (%)	4 (0.8)

Reported using haematinics, n (%)	427 (84.7)

Morbidity and Outcomes

Reported fever previous week, n (%)	82 (16.2)

Used antimalarial for fever, n (%)	10 (1.9)

Maternal fever at delivery3, n (%)	35 (6.9)

Birth weight± (g), mean (SD)	2621 (450)

Birth weight <2500 g, n (%)	176 (37.1)

Baby’s gestational age in weeks4, mean, (SD)	37.2 (1.3)

Preterm babies <37 weeks), n (%)	95 (20.0)

Stillbirths≠, n (%)	22 (4.4)

Stillbirths in uninfected women, n (%)	18 (3.6)

Maternal Hb (g/dL), mean (SD)	10.5 (2.2)


Toxicity	Overall incidence, no. (%)	Grade 1 and 2, no. (%)	Grade 3 and 4, no. (%)

Hyperglycemia	19 (79)	19 (79)

Fatigue	19 (79)	18 (75)	1 (4)

Thrombocytopenia	12 (50)	12 (50)

Headache	11 (46)	10 (43)	1 (4)

Nausea	10 (42)	9 (38)	1 (4)

Leukopenia	9 (38)	9 (38)

ALT elevations	8 (33)	8 (33)

AST elevations	7 (29)	7 (29)

Bilirubin elevations	5 (21)	5 (21)

Neutropenia	5 (21)	5 (21)

Anemia	5 (21)	4 (17)	1 (4)

Seizures	5 (21)	4 (17)	1 (4)

Vomiting	5 (21)	4 (17)	1 (4)

Thyroid toxicity	4 (17)	4 (17)

Diarrhea	4 (17)	4 (17)

Myalgias/Arthralgias	3 (13)	3 (13)

Rash	2 (8)	2 (8)

Pyrexia	2 (8)	2 (8)

Lipase	1 (4)	1 (4)

Amylase	1 (4)	1 (4)

Mucositis	1 (4)	1 (4)


Age	87 years

Symptoms	Nocturnal leg cramps of moderate intensity since years. Since three weeks intensity of symptoms increased despite the use of quinine for symptomatic relief

Medical history	myocardial infarction in 2002 with consecutive coronary artery bypass graft (CABG)arterial hypertensionchronic kidney disease IIIknee replacement left + right.

Medication	aspirin 100 mg 1-0-0bisoprolol 2,5 mg 1-0-0ramipril 5 mg 1-0-0simvastatin 40 mg 0-0-1vitamin D3 1000 IU 1-0-0torasemide 5 mg 1-0-0fentanyl patch 12,5 μg once every 3 days.Self-medication: quinine200 mg once daily


Possible outcome in eradication studies	How does the outcome affect reservoir measures?

1. Preferential reduction in intact proviruses	Integrated HV DNA is likely to be unchanged. Proviral sequencing would likely detect a reduction in the fraction of replication-competent proviruses which could be combined with integration measures to determine the absolute reduction in intact proviruses

2. Preferential reduction in defective proviruses	Integrated HIV DNA would decrease, without reflecting a contraction in the size of the “true” reservoir. Proviral sequencing would likely capture the change in the fraction of defective proviruses

3. Decrease in both intact and defective proviruses	If intact and defective proviruses are targeted differently, a decrease in integrated HIV DNA would occur, but would not likely be proportional to the decrease in the number of intact proviruses. Proviral sequencing combined with integration measures would likely capture the changes in the reservoir size and character


Time point	N 	PD	F 	P value

Mean ± SD

Baseline 	25	61.04 ± 10.45	5.399 	0.00*

Second week 	25	66.60 ± 10.74

Fourth week 	25	69.64 ± 9.45

Sixth week 	25	71.40 ± 8.23


Paper	Country	Time period of breast cancer deaths	Cases (n)	Screening exposure	Crude Ors (95% CI)	ORs adjusted for self-selection bias

Allgood et al. [15]	UK	1995-2004	284	Ever/Never attendance before (pseudo) diagnosis	0.35 (0.24-0.51)	0.52 (0.32-0.84)

Fielder et al. [16]	Wales	1998-2001	419	Ever/Never attendance before (pseudo) diagnosis	0.62 (0.47-0.82)	0.75 (0.49-1.14)

Gabe et al. [17]	Iceland	1990-2002	226	Ever/Never attendance before (pseudo) diagnosis	0.59 (0.41-0.84)	0.65 (0.39-1.09)

Paap et al. [18]	Netherlands	2004-2005	118	Screened at index invitation	0.30 (0.14-0.63)	0.24 (0.10-0.58)

Puliti et al. [19]	Italy	1988-2002	1750	Ever/Never attendance before (pseudo) diagnosis	0.46 (0.38-0.56)	0.55 (0.36-0.85)

Roder et al. [20]	Australia	2002-2005	491	Ever/Never attendance before (pseudo) diagnosis	0.59 (0.47-0.74)	0.70a


	n (%)	L1CAM expression n (%)	n (%)

Negative	≤ 20% of tumor cells	>20% of tumor cells		P value

Recurrence	9 (16)	14 (24)	34 (60)	57

No recurrence	24 (43)	19 (34)	13 (23)	56	< 0.0001


	Fully vaccinated, positive responsesan = 75n (%)	Non-vaccinated positive responsesan = 119n (%)	Fisher’s exact testp-value

Knowledge items

 HPV is a sexually transmitted infection	73 (97.3)	106 (89.8)	0.08

 Men and women can be carriers of HPV	74 (98.7)	108 (91.5)	0.05

 HPV vaccine protects against genital warts	58 (77.3)	86 (72.3)	0.50

 HPV vaccine protects against cervical cancer	72 (96.0)	104 (87.4)	0.07

 HPV vaccine protects against other cancers	36 (48.0)	56 (47.9)	1.00

 HPV vaccine is safe	71 (95.9)	102 (85.7)	0.03*

 HPV vaccine is effective	71 (95.9)	104 (87.4)	0.07

 HPV vaccine has few side effects	64 (85.3)	83 (70.3)	0.02*

 HPV vaccination leads to lasting immunity	49 (65.3)	58 (49.2)	0.04*

 HPV vaccine is recommended for girls and boys	68 (90.7)	83 (70.3)	<0.001*

Attitude items

 HPV vaccination may lead to risky sexual behavior	4 (5.3)	10 (8.4)	0.57

 I have enough information to be able to counsel about HPV vaccine	35 (46.7)	45 (38.1)	0.29

 I feel comfortable counseling about HPV vaccination	34 (45.3)	44 (37.3)	0.29

 I would recommend the HPV vaccine to friends and family	73 (97.3)	81 (69.2)	<0.001*

 HPV vaccine should be mandatory	53 (72.6)	44 (38.3)	<0.001*


Gene	Sequence (5' to 3')

Abcc4

 - forward	TGCTTCCCAGACTCTGCACAAC

 - reverse	AAGCAAGTCGTCCATGTGTCCG

Akr1c9

 - forward	CAAGTGCCTTTGAATGCTGAGCC

 - reverse	ACACCCACTTCATGCCCAAGAC

AR

 - forward	AGAAAAAATCCCACATCCTGC

 - reverse	CATCATTTCAGGAAAGTCCACG

Dhcr24

 - forward	TGCTGAACTCCATTGGCTGGAC

 - reverse	TTGTGGGACGATGACTCGATGC

Facl3

 - forward	TCAGGCCAAGGCAAACTCCATTC

 - reverse	TGCCAAAGCAAACTGGAGGAGG

Gucy1a3

 - forward	AAGCTGAAGGCAACCTTGGAGC

 - reverse	TTTGTCCTTGCCAGAGCTGCTG


	Proteins with high IS	P-value

100 most abundant proteins with IS in L. interrogans	7	.0067

100 most abundant non-ribosomal proteins with IS in L. interrogans	9	.033

100 most abundant non-ribosomal proteins with IS in E. coli	6	.0013

100 most abundant non-ribosomal proteins with IS in E. coli	9	.033


 	Children with ESRD

 	(n=92)

Age (years)	13.1 (0.7-19.1)

Male*	51 (55%)

Weight (kilograms)	37.8 (4.3-96.0)

BSA (m2)	1.2 (0.4-2.2)

Height (cm)	138 (61–184)

Duration of RRT (years)	1.8 (0.0-6.8)

Modality at time of Echocardiography*

-Hemodialysis	26 (28%)

-Peritoneal dialysis	24 (26%)

-Transplantation	42 (46%)


Totle SNP	Non coding SNP	Coding SNP	Synonymous	Nonsynonymous

12,518	8863(70.80 %)	3655(29.20 %)	3632	23


	Incidence before varicella vaccination (per 1000 population)	Reduction since varicella vaccination* (%)

USA	Uruguay	USA	Uruguay

<1 year	19.7	14.3	68–81	63–80

1–4 years	48.8	56.7	83–90	94–97

5–9 years	34.5	41.6	63–77	73–81

10–14 years	9.5	13.2	65–80	62–65


First author	Year	Country	Racial/descent	Source of controls	Case	Control	Genotype distribution	Pfor HWEa	Genotying type

Case	Control

GG	GA	AA	GG	GA	AA

Catarino	2005	Portugal	Caucasian	Healthy base	143	103	35	64	44	9	55	39	0.091	PCR-RFLP

Jeon	2005	Korean	Asian	Hospital base	222	314	49	112	61	80	160	74	0.730	PCR-RFLP

Catarino	2008	Portugal	Caucasian	Hospital base	226	247	60	103	63	40	138	69	0.037	PCR-RFLP

Satinder	2008	India	Asian	Healthy base	150	150	33	64	53	30	65	55	0.184	PCR-RFLP

Thakur	2009	India	Asian	Hospital base	200	200	39	94	67	47	119	34	0.006	PCR-RFLP

Castro	2009	Sweden	Caucasian	Population base	952	1713	229	463	260	465	837	411	0.367	Multiplex PCR and hybridization

Ni	2011	China	Asian	Hospital base	300	312	48	160	92	70	137	105	0.051	PCR-RFLP

Warchoł	2011	Poland	Caucasian	Healthy base	129	288	35	65	29	116	123	49	0.100	PCR-RFLP

Wang	2012	China	Asian	Population base	327	411	86	180	61	92	203	116	0.859	PCR-RFLP

Djansugurova	2013	Kazakhstan	Caucasian	Healthy base	215	160	54	103	58	41	78	41	0.752	Direct sequencing


	ASD	TD

Head ROI

 Implicit mentalizing-action	4.64 (9.68)	2.32 (12.01)

 Implicit either-action	4.32 (8.00)	0.37 (11.08)

 Explicit mentalizing-non-mentalizinga	0.06 (18.05)	1.91 (13.13)

Poker chip ROI

 Implicit mentalizing-action	1.16 (6.15)	− 1.83 (8.76)

 Implicit either-action	2.36 (5.58)	2.12 (11.96)

 Explicit mentalizing-non-mentalizinga	4.12 (15.89)	0.75 (6.21)

Release point ROI

 Implicit mentalizing-action	− 5.34 (3.98)	− 1.99 (5.52)

 Implicit either-action	− 6.04 (4.24)	− 3.67 (4.76)

 Explicit mentalizing-non-mentalizinga	− 3.53 (6.81)	− 3.82 (2.70)


Name	Genome size (Mbp)	GC Content (%)	Coverage (X)	Scaffolds	N50	Protein coding genes	Reference

AMDSBA1	4.56	52.19	258	155	65,127	4629	This study

AMDSBA2	3.07	52.37	10	409	10,877	3312	This study

AMDSBA3	3.68	55.54	113	129	49,240	3785	This study

AMDSBA4	4.11	51.67	25	179	63,277	4254	This study

AMDSBA5	3.65	49.15	92	161	65,096	3870	This study

S. thermosulfidooxidans AT-1 (DSM 9293)	3.86	49.64	N/D	2	-	3875	IMG JGI

S. thermosulfidooxidans ‘Cutipay’	3.86	49.30	116	35	509,367	3600	Travisany [16]

S. acidophilus NALT (DSM 10332)	3.56	56.75	168	1	-	3626	Anderson [17]

S. acidophilus ‘TPY’	3.55	56.70	26	1	-	3770	Li [2]


 	Frequency of complication	In-hospital deaths	Relative risk of in-hospital death

 	N	%	N	%	Adj. RR	95% CI

No complication	18,415	77.5	108	0.6

Complication

Gastrointestinal	263	1.1	18	6.8	3.61	2.32-5.63

Respiratory	636	2.7	44	6.9	2.05	1.30-3.03

Urologic	546	2.3	102	18.7	3.62	2.62-5.00

Infection	449	1.9	18	4.0	2.45	1.47-4.07

Bleeding or acute posthaemorrhage anemia	4,371	18.4	188	4.3	2.11	1.73-2.57

Bleeding or acute posthaemorrhage anemia requiring blood transfusion	3,086	13.0	157	5.1	1.96	1.57-2.44


Transformable isolateb	Phylogenetic position	Plasmids tested	16S-rRNA gene identityc

Marinobacter sp.	Gammaproteobacteria;	pM1, pM2,	77

	Alteromonadales	pM3

Kocuria rosea	Actinobacteria;	pM2	79

Photobacterium	Gammaproteobacteria;	pM1, pM2,	86

phosphoreum	Vibrionales	pM3

Psychrobacter	Gammaproteobacteria;	pM1, pM2,	96

marincola	Pseudomonadales	pM3


	Cardinal clinical feature

	Ataxia(n = 54)	Tremor(n = 4)	Cognitive deficits(n = 28)	Total(N = 86)

Age (mean ± SD)	67.7 ± 9.1	59.0 ± 8.6	70.0 ± 9.2	68.0 ± 9.3

Age-of-onset (mean ± SD)	59.0 ± 6.8	54.0 ± 1.4	60.5 ± 6.7	59.2 ± 6.7

With additional cardinal features (n)	13	1	4	18

Family history (n)

None	33	3	14	50

Unknown	21	1	14	36


Variable	Mothers	Fathers

	Mean (sd)	Mean (sd)

Age (when index child born)	33.2 (4.7)	34.7 (5.7)

Parental education:

No qualifications	–	1 (0.7%)

GCSE	8 (5.5%)	13 (8.9%)

A levels or equivalent	14 (9.6%)	13 (8.9%)

Diploma or equivalent degree	27 (18.5%)	25 (17.1%)

Degree	46 (31.5%)	51 (34.9%)

Postgraduate	46 (31.5%)	40 (27.4%)

Missing	5 (3.4%)	3 (2.0%)

Parental occupation:

Managerial/professional	81 (55.5%)

Intermediate occupations	39 (26.7%)

Routine/manual	25 (17.1%)

Unemployed	1 (0.7%)


Cox proportional hazard ratios	Sites discovered before E.O. [Exp(B)]	Chance of listing (%)a	Sites discovered after E.O. Exp(B)	Chance of listing (%)a

Marginalized populations

 Hispanic (%)	1.002	2	1.005	5

 American Indian (%)	1.003	3	0.923	−77

 Minority (%)	0.998	−2	0.993	−7

 Institutionalized population (%)	1.002	2	0.998	−2

 Elder population (%)	0.999	−1	1.042	42

Wealth and power indicators

 Mean family income ($1,000s)	1.004	4	1.004	4

 Mean value of housing ($1,000s)	0.999	−1	1.006	6

 Owned housing (%)	1.001	1	1.019	19

 Professional careers (%)	1.007	7	0.934	−66

 College degree or higher (%)	1.001	1	0.975	−25

 No high school diploma (%)	1.000	0	1.010	10

 Below the poverty line (%)	0.984	−16	0.969	−31

Gender and family

 Female headed households (%)	1.005	5	1.048	48

 Children < 18 (%)	1.000	0	0.991	−9

Urbanization

 Population density	1.000	0	1.000	0

 Urban	0.998	−2	1.002	2

Site-specific characteristics

 PRPs identified	1.344	134	0.617	62

 Hazardous ranking score	0.977	−23	0.987	−13

Cases

 Listed	1,410		53

 Censored	48		8

 Total	1,458		61

 Missing	21		0


Plant family/Plant sample - Herbarium voucher number	Traditional use	Part used in this study	Potential active compounds characterized	Previously screened activity

APOCYNACEAE/Alstonia boonei De Wild – 43368/HNC	Fever, painful micturition, insomnia, chronic diarrhea, rheumatic pains, anti-venom (snake bites), malaria, diabetes, helminths, arthritis [28, 29].	Leaves, bark	Echitamine, echitamidine, Voacangine, akuammidine, N- α-formylechitamidine, N- α-formyl-12-methoxyechitamidine [29].	Antimalarial, antioxidant, analgesic, anti-inflammatory, antipyretic [30–32].

APOCYNACEAE/Catharanthus roseus L. – 5689/HNC.	Bleeding arresting, diabetes, fever, rheumatism, cancer [20, 33].	Leaves, stem	Vincristine, vinblastine, benzoic acid, p-hydroxybenzoic acid, salicylic acid, 2,3-dihydroxybenzoic acid, 2,5-dihydroxybenzoic acid, 3,4-dihydroxybenzoic acid, 3,5-dihydroxybenzoic acid, gallic acid, vanillic acid, chlorogenic acid, kaemferol trisaccharides, Quercetin trisaccharides, Syringetin glycosides [20, 34].	Wound-healing, antimicrobial, hypoglycemic, antioxidant [18, 20, 33].

ASTERACEAE/Ageratum conyzoïdes Linn. – 19050/SFR-Cam	Purgative, fever, ulcers, wound, mental, infectious diseases, headaches, anti-inflammatory, diarrhea [35, 36].	Whole plant	β-caryophyllene, precocene I, friedelin, Lycopsamine, echinatine,β-sitosterol, stigmasterol, 5-methoxynobiletin, linderoflavone B, eupalestin, sabinene, α and β pinene, β-phellandrene, 1,8-cineole and limonene, ocimene, eugenol [35].	Antimicrobial, anticonvulsant, analgesic, anti-inflammatory, antipyretic, insecticidal, antioxidant, antiplasmodial, cytotoxic [35, 37, 38].

EUPHORBIACEAE/Croton macrostachys Hochst. – 40501/HNC	Malaria, antidiabetic, purgative mastitis, wounds, gastrointestinal Complications [39–41].	Leaves	Neoclerodan-5,10-en-19,6β;20,12-diolide; 3α,19-Dihydroxytrachylobane; 3α,18,19-Trihydroxytrachylobane, lupeol, lupenone, betulinic acid, 28-O-acetylbetulin, betulin, lupeol acetate, zeorin, benzoic acid, methyl gallate, methyl 2,4-dihydroxy-3,6-dimethylbenzoate, lichexanthone, β-sitosterol, and β-sitosterol palmitate, stigmasterol, botulin, crotepoxide [42, 43].	Antimicrobial, antimalarial, cytotoxic [38, 39, 41].

FABACEAE/Cassia obtusifolia L. – 39847/HNC	Laxative, eye infections, diarrhea, urinary tract infections, gingivitis, fever, cough [25].	Whole plant	aloe-emodin, 1-methylaurantio-obtusin-2-O-β-D-glucopyranoside, emodin, 1,2- dihydroxyanthraquinone, obtusin, chrysoobtusin, aurantioobtusin, gluco-obtusifolin, glucoaurantioobtusin, gluco-chryso-obtusin, 1-desmethylaurantio-obtusin, 1-desmethylaurantio-obtusin-2-O-β- D-glucopyranoside, 1-desmethylchryso-obtusin, 1-desmethyl-obtusin, aurantio-obtusin-6-O-β-D-glucopyranoside, alaternin-1-O-β-D-glucopyranoside, chrysoobtusin-2-O-β-D-glucopyranoside physicon-8-O-β-D-glucoside, obtusifolin, O-methyl-chrysophanol, emodin-1-O-β-gentio-bioside, chrysophanol-1-O-β-gentiobioside, physcion-8-O-β-gentiobioside, physcion-8-O-β-glucoside, chrysophanol-1-O-β-D-glucopyranosyl-(13)-β-D-glucopyranosyl-(1 → 6)-β-D-glucopyranoside, chrysophanic acid, physcion, questin, 1,3-dihydroxy-8-methylanthraquinone, chrysophanol- 10,10′-bianthrone, torosachrysone [44].	Antibacterial, antifungal, mosquito larvicidal activity, platelet antiaggregatory, neuroprotective [25, 45–47].

SAPINDACEAE/Paullinia pinnata L. – 10702/SRF-Cam	Malaria, erectile dysfunction [24].	Leaves, stem	Paullinoside A, paullinomides A and B, β-amyrin, 13β,17β-dihydroxy-28-norolean-12-ene, β-sitosterol glucopyranoside, 2-O-methyl-L-chiro-inositol, L-quebrachitol, β-sitosterol, friedelin, daucosterol, aridanin, lotoidoside [24, 48].	Antiparasitic, antimicrobial, cytotoxic [24, 38, 49].


Age (Year)	Calibration Model	Total Body Burden (Bq)	Estimated Total Uptake (Bq)	24-h Thyroid Uptake (%)

53	Homogenous	3927 ± 135	4243 ± 146	-

Thyroid and others	3716 ± 128	4015 ± 138	<7.2 ± 1.1

49	Homogenous	2321 ± 165	2508 ± 178	-

Thyroid and others	2320 ± 165	2507 ± 178	<10.7 ± 3.8

35	Homogenous	3918 ± 127	4233 ± 137	-

Thyroid and others	4050 ± 131	4376 ± 142	<16.7 ± 2.7

34	Homogenous	1284 ± 182	1387 ± 197	-

Thyroid and others	1140 ± 162	1232 ± 175	<49.9 ± 11.0

27	Homogenous	2623 ± 195	2834 ± 211	-

Thyroid and others	2454 ± 182	2652 ± 197	<44.1 ± 5.8


	t3

No/little burden	Moderate burden	(Very) severe burden

t1	No/little burden	22	3	0	25 (48.1 %)

Moderate burden	7	8	3	18 (34.6 %)

(Very) severe burden	0	4	5	9 (17.3 %)

		29 (55.8 %)	15 (28.8 %)	8 (15.4 %)	52 (100 %)